



Published in final edited form as:

Adv Exp Med Biol. 2017 ; 1008: 253–282. doi:10.1007/978-981-10-5203-3_9.

Understanding the Role of lncRNAs in Nervous System Development

Brian S. Clark, Ph.D. and **Seth Blackshaw, Ph.D.**

Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract

The diversity of lncRNAs has expanded within mammals in tandem with the evolution of increased brain complexity, suggesting that lncRNAs play an integral role in this process. In this chapter, we will highlight the identification and characterization of lncRNAs in nervous system development. We discuss the potential role of lncRNAs in nervous system and brain evolution, along with efforts to create comprehensive catalogues that analyze spatial and temporal changes in lncRNA expression during nervous system development. Additionally, we focus on recent endeavors that attempt to assign function to lncRNAs during nervous system development. We highlight discrepancies that have been observed between *in vitro* and *in vivo* studies of lncRNA function and the challenges facing researchers in conducting mechanistic analyses of lncRNAs in the developing nervous system. Altogether, this chapter highlights the emerging role of lncRNAs in the developing brain and sheds light on novel, RNA-mediated mechanisms by which nervous system development is controlled.

Keywords

Development; Neuron; Brain; Transcription; Evolution

9.1 Evolution of the Brain and Emergence of lncRNAs

The emergence of a true nervous system can be traced back to the evolution of the Bilateria, organisms that displayed two sides that are virtual mirror images, a hollow gut tube and a clustering of nerve cells into a nerve cord. The brain evolved from the clustering of the nerve cells at the anterior pole of the organism, connecting to other clusters of nerve cells, or ganglia, distributed along the central nerve cord. With the evolution of the vertebrates, this ventrally located nerve cord evolved into the dorsally located spinal cord. Likewise, throughout evolution, nervous system development is controlled by a largely conserved set of transcription factors and signaling molecules [1, 2]. Many of the same gene sets are even present and function orthologously in the more evolutionary primitive “nerve nets” of Cnidaria [3, 4]. These findings raise the question: How do the same gene sets function to control the great diversity of structures and cell types that are found in the nervous system across evolution? While some of this diversity is undoubtedly generated by gene duplications and repurposing of orthologous gene functions [5, 6], other mechanisms are

certainly at work. These questions are most pertinent for the development of highly complex mammalian brains, particularly those of higher primates. In this section, we explore the potential central role of lncRNAs in the evolution of the mammalian nervous system.

During vertebrate and more specifically hominid evolution, the brain has undergone an evolutionarily rapid expansion in size. In mammals with larger, more convoluted cortices, the expansion in size correlates with an expanded diversity of progenitor cells [7] that possess an increased proliferative capacity [8–14]. In primates, the greatly increased size of the cerebral cortex appears to result from a dramatic expansion of progenitors in the outer subventricular zone [15, 16]. Interestingly, when brain size is normalized to body size using the encephalization quotient (EQ), the expansion in size of the brain across mammalian evolution shows a strong, nonlinear correlation with the expansion in the numbers of individual lncRNAs (Fig. 9.1).

Consistent with the notion that lncRNAs have co-evolved with the expanded repertoire of brain functions, a majority of lncRNAs examined to date display specific expression within neuroanatomical regions or neuronal cell types in mouse [22, 23]. Many of these brain-enriched lncRNAs are co-expressed with, and display genomic localizations in close proximity to, known neurodevelopmental regulators [24] and likely regulate similar processes during neurodevelopment. Together, this has led to the general hypothesis that the expanded diversity in lncRNAs is pivotal to the expansion in higher-order cognitive ability of humans and primates and the diversity of neuronal cell types and function. Accordingly, roughly one-third of ~13,800 lncRNAs examined are specific to the primate lineage, with ~40% of the lncRNAs displaying nervous system-specific expression [19, 25–27]. The emergence of brain-specific lncRNAs during primate/human evolution likely occurred through gene duplication, since brain-specific lncRNAs are more likely to originate from genomic regions that have undergone recent duplication than are more ubiquitously expressed or non-brain-enriched lncRNAs [25, 28, 29]. With the continued annotation of genomes and transcriptomes of various species across evolution, we are better able to assess the evolutionary conservation of lncRNAs and their role in the emergence of human-specific traits [30].

Interestingly, although lncRNAs display poor overall primary sequence conservation when compared to protein-coding genes [29, 31], brain-specific lncRNAs display two interesting evolutionary attributes: (1) brain-specific lncRNAs display higher sequence conservation than lncRNAs expressed in other tissues [24, 32] and (2) the spatiotemporal expression patterns of orthologous brain-enriched lncRNAs are maintained across multiple species [32]. This suggests that the expansion in the number of lncRNAs has played a critical role in the development of brain structures throughout the mammalian lineage. To further support the hypothesis that lncRNAs are vital to the evolutionary expansion of relative brain size and cognitive ability, researchers have identified genomic loci that display high conservation throughout vertebrate evolution but have undergone rapid evolution in humans [33–36]. These sequences are postulated to, therefore, play a role in human-specific brain functions. ~2700 “human accelerated regions (HARs),” which had selectively undergone rapid evolution following the divergence of the ancestors of humans and chimpanzees, were identified in these studies. Most HARs mapped to noncoding regions throughout the human

genome. Of these, an estimated 30% of HARs mapped to identified brain-specific enhancers. A total of 15 HARs mapped to sequences annotated as long intergenic noncoding RNAs [37]; however, the extent to which the majority of HARs overlap unannotated, intronic, or antisense lncRNAs remains to be analyzed.

Most notably, researchers identified one specific HAR, HAR1, which overlaps the *HAR1F* brain-expressed lncRNA [35]. HAR1 showed the most accelerated substitution rate of any genomic region examined (18 bp of substitution in 118 bp since the last common ancestor of humans and chimpanzees). The *HAR1F* lncRNA was further examined and is expressed developmentally in the Cajal-Retzius neurons of the cortex, the upper cortical plate, the hippocampal primordium, dentate gyrus, cerebellar cortex, and a handful of hindbrain nuclei. *HAR1F* expression in both cortical and extra-cortical regions overlapped with expression of reelin, a known regulator of neurodevelopment. Of particular interest are the Cajal-Retzius neurons. The Cajal-Retzius cells populate the subpial granular layer, a region of the brain that is enlarged in humans [38–41]. To date, the function of *HAR1F*, and many other HARs, remains unknown. It will be of great interest to determine the role of *HAR1F* in Cajal-Retzius cell development.

Aside from HARs that overlap annotated lncRNA sequences, the degree of lncRNA contribution to the evolution of the brain is difficult to assess, given the poor degree of primary sequence conservation that is seen for most lncRNAs [42]. To further address the evolutionary emergence and contributions of lncRNAs in organisms with more complex brains, researchers examined “micro-synteny” of human genomic regions that contained lncRNAs across both large- and small-brained species [43]. These efforts first identified 187 human lncRNAs that are differentially expressed in progenitors or mature neurons of the developing embryonic human brain. When comparing the degree of conservation in genomic architecture surrounding the lncRNA across 30 species (29 mammals plus the chicken), species with large brains (high gyrencephalic indices (GI) >1.5; corresponding on average to approximately one billion cortical neurons [11]) displayed higher than expected conservation of the syntenic genomic landscape surrounding the lncRNA [43]. Conversely, smaller-brained species, with fewer sulci and gyri, displayed lower than expected lncRNA gene-neighborhood conservation. There were, however, two key exceptions: (1) the marmoset, a low-GI primate thought to have recently evolved from a high-GI ancestor [44], and (2) the manatee, a large but lissencephalic species [45]. Both of these species had higher than anticipated degrees of micro-synteny conservation. Importantly, when examining lncRNAs that are expressed in non-neuronal cells across all species, there was no similar correlation between the degree of micro-synteny and brain size [43]. This data suggests an evolutionary pressure to maintain the genomic architecture of regions that include lncRNAs, which in turn is likely to be important for regulation of neurogenesis and brain size. Further supporting this hypothesis, the researchers observed that the degree of micro-synteny conservation of lncRNAs was highest when the lncRNAs were positioned in close proximity to transcription factors that control neuronal development [43].

Additional research both identifying and characterizing nervous system-expressed lncRNAs will continue to aid in our understanding of the evolutionary changes that have enabled the development of the human brain. Our current understanding of the identity (Sect. 9.2) and

function (Sect. 9.3) of lncRNAs involved in nervous system development comprises the remainder of the chapter.

9.2 Building a Catalogue of lncRNAs Expressed in the Developing Nervous System

While functional studies on lncRNAs in nervous system development are still lagging considerably (see Sect. 9.3), transcriptomic analyses have identified thousands of lncRNAs. In fact, with much greater coverage of the developing and mature brain by RNA-Seq analysis, recent studies have identified numbers of lncRNAs within given species that approach, or even exceed, the number of protein-coding genes [46]. For example, the NONCODEv4 collection estimates ~56,000 or ~46,000 independent lncRNAs for human and mouse, respectively [47].

While these numbers likely overestimate the true number of lncRNA transcripts, we expect the number of validated lncRNAs to increase beyond the annotated numbers from GENCODE (~15,000 for human, ~9000 for mouse [19]) for two main reasons. First, recent analysis has revealed that lncRNAs show a higher degree of tissue- and cell-type specificity than protein-coding genes [22, 23, 48–52]. It is thus almost certain that large numbers of lncRNAs may have escaped detection in previous RNA-Seq experiments—in particular, many have likely been lost in libraries prepared from bulk tissue, due to highly specific expression in rare cell types and/or low levels of overall expression. This is especially relevant in the nervous system, where the numerous brain structures and nuclei are comprised of highly diverse neuronal subtypes. Advances in single-cell RNA sequencing (scRNA-Seq) along with systematic characterization of individual cell types through efforts such as the BRAIN Initiative [53] will overcome these technical limitations. The power of scRNA-Seq analysis was underlined in a recent study that identified >5500 novel lncRNAs from single cells of the mouse cleavage stage embryo [54]. In addition, experimental design may also be limiting our detection of lncRNAs. Many RNA-Seq experiments are designed to capture only polyadenylated transcripts, in order to deplete the fraction of regulatory RNAs from the sequencing runs. While many lncRNAs are polyadenylated, significant fractions of lncRNAs persist as non-polyadenylated transcripts [19]. Moreover, detection and identification of antisense lncRNAs remains difficult unless strand-specific RNA-Seq libraries are generated, a technique currently not employed for many publically available datasets.

The second reason is our rapidly advancing understanding of the immense complexity of the mammalian transcriptome. Our current knowledge of the transcriptome is substantially limited by the sequencing technologies we employ. Sequencing reads that do not map in a linear fashion to the reference genome are frequently discarded as aberrant or false sequences. The presence of circular RNAs is an example of novel lncRNA species that have only recently been detected in large numbers through more rigorous analyses of RNA-Seq datasets [55–58]. Additional complexity of the transcriptome is being uncovered through the use of targeted RNA-Seq or Capture-Seq [59]. This has identified intragenic splicing events

and enabled reliable identification of novel lncRNAs, including lowly expressed or rare lncRNA variants [60–62].

Many studies have begun to examine the expression of lncRNAs in embryonic stem (ES) that have undergone controlled differentiation both in vitro and within progenitor and neural precursor cells within the native developing nervous system in vivo. Here, we summarize these results.

9.2.1 Identification of lncRNAs from In Vitro Studies

Many exploratory studies characterizing lncRNA expression during neuronal development, particularly those assessing human development, focus on analysis of neural progenitors generated through in vitro controlled differentiation from pluripotent stem cells. These studies allow researchers to both easily obtain large quantities of relatively pure cells for in-depth analysis of transcript profiles and to control the precise developmental environment to analyze temporal changes in gene expression. The high degree of cell purity that can often be obtained using these approaches also aids in the detection of transcripts expressed at low levels, a category that includes many lncRNAs. A series of recent studies have shed considerable light on the identity of lncRNAs expressed in pluripotent stem cells and the highly dynamic patterns of lncRNA expression seen during directed differentiations toward specific neuronal cell type fates.

Initial studies of pluripotent stem cells reported that twice as many lncRNAs were selectively expressed in undifferentiated ES cells relative to more differentiated stages [63]. This is consistent with previous observations that analyzed the number of protein-coding genes expressed during pluripotent stages [64–66] and is also consistent with the high overall fraction of the genome that is present as euchromatin in ES cells [67–69]. All told, studies have identified over 250 lncRNAs that are selectively expressed in pluripotent stem cells [63, 70, 71].

Other studies have aimed to identify lncRNAs that are candidates for controlling neuronal identity based on differential expression of lncRNAs during progressive differentiation of stem cells toward neuronal lineages. In one study, researchers examined the expression profiles of lncRNAs during the differentiation of mouse embryonic forebrain-derived neural stem cells using microarrays [72]. These studies examined the bipotent sonic hedgehog-responsive, *Nkx2.1*-positive stem cells that generate both cortical GABAergic interneurons and oligodendrocytes. Comparing the bipotent progenitor cells, GABAergic interneurons, oligodendrocytes, and oligodendrocyte progenitor cells to neural stem cells, the researchers identified 169 lncRNAs (out of 3659 probes on the arrays) with differential expression during neural progenitor cell differentiation. Of particular interest, four lncRNAs were selectively activated upon GABAergic neuronal commitment. One of these, *Ak044422*, appears to function as a pre-miR for *miR-124a*, which accounts for nearly half of all brain-expressed miRNAs [73]. *miR-124a* is known to promote neuronal differentiation at least in part through repression of *Ptbp1* [74]. Consistent with this, *Ak044422* shows complementary expression to *Ptbp1* during neuronal differentiation [72]. However, the researchers suggest that expression of *Ak044422* transcript in the mature nervous system, and posttranscriptional modifications that include alternative splicing and polyadenylation,

imply that the *Ak044422* transcript may have additional functions in nervous system development independent of *miR-124a*. This same study identified 100 additional lncRNAs that displayed differential expression upon oligodendrocyte progenitor specification [72].

Similar experiments profiling lncRNA expression were performed on the directed differentiations of human ES cells to dopamine neurons [75]. Microarray profiling of lncRNA expression in ES cells, neurogenic progenitors, and mature dopamine neurons were used to identify lncRNAs that were candidates for regulating maintenance of pluripotency or neurogenic commitment. Over 900 lncRNAs were identified as differentially expressed during neurogenic commitment, with three lncRNAs identified as exclusively expressed in undifferentiated ES cells and 35 lncRNAs highly enriched in neural progenitor cells.

Together, these studies have provided a foundation for examining the considerable diversity of lncRNA expression during neurogenic differentiation and neuronal cell fate commitment. However, in most cases, the extent to which the in vitro expression of individual lncRNAs correlate with their in vivo expression patterns remains undetermined.

9.2.2 lncRNAs Identified Through In Vivo Studies of Neuronal Differentiation

While in vitro studies of cultured cells have provided a wealth of data identifying lncRNA expression with respect to neuronal differentiation from pluripotent stem cells, the extent of lncRNA expression in the nervous system has been further advanced through the profiling of primary tissue samples. Techniques such as customized microarrays for lncRNAs, serial analysis of gene expression (SAGE), and RNA-Seq analysis of primary nervous system tissue have identified thousands of lncRNAs expressed in the nervous system of multiple species [19, 20, 22, 23, 30, 46–50, 61, 76–78]. Additionally, highly cell and tissue-specific lncRNAs can be identified by expression profiling of micro-dissected or sorted tissue and/or cell populations.

Early studies examined the global transcript expression across a time series of retinal development using SAGE [49], identifying multiple noncoding transcripts that showed both temporally dynamic and spatially restricted expression patterns. These analyses identified and examined the retinal expression patterns of lncRNAs including *Six3os* (*Rncr1*), *Neat1* or *Gomafu* (*Rncr2*), and *RncrR3* (the previously mentioned *Ak044422*). Importantly, these studies indicated that some lncRNAs display exceptionally high levels of expression during retinal development, including *Rncr2* which comprised ~0.2% of all polyadenylated RNA transcripts in the neonatal retina [49, 79].

More recent studies have begun to examine the complexity of the transcriptome within defined progenitors and neuronal cell types. In one such study, researchers examined the diversity of transcript expression within three defined subtypes of cortical pyramidal neurons including the sub-cerebral projection neurons, callosal projection neurons, and corticothalamic projection neurons [80]. RNA-Seq analysis of FACS-sorted cells across neurodevelopment identified 806 lncRNAs with significant differential expression between cell types and developmental stages. Four hundred forty-nine of these lncRNAs were selectively expressed in one of these pyramidal cell subtypes, supporting the high degree of cell-type specificity of lncRNAs [23].

lncRNA expression in adult neural stem cells of the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) has been profiled extensively. The first study to address this question was a large-scale in situ hybridization analysis conducted by the Allen Brain Atlas. This effort identified 849 brain-expressed lncRNAs, a number of which were selectively expressed in adult neural stem cells [22]. Later studies have examined the expression of lncRNAs within neurogenic progenitor niches of the adult mouse subventricular zone [77]. Transcript profiles were compared to neurons of the mature olfactory bulb, to which the differentiating cells of the SVZ migrate, neural stem cells of the SGZ, ES cells, and ES cell-derived neurogenic progenitors. This study identified 6876, 5044, or 3680 novel lncRNA transcripts beyond those annotated in the RefSeq, UCSC, or Ensembl reference genome builds, respectively [77]. Consistent with previous reports, lncRNAs displayed more highly spatially and temporally restricted expression than protein-coding genes. To further profile these cell types, RNA Capture-Seq was used and identified an additional 3500 lncRNA transcripts within the SVZ, olfactory bulb, and dentate gyrus [77].

As previously mentioned, additional lncRNAs continue to be identified as sequencing technology advances, particularly with the recent optimization of single-cell RNA-Seq [54]. Recently, researchers profiled the transcript profiles of both bulk tissue samples and individual cells from micro-dissected human neocortices [78]. In bulk-sequencing experiments of tissue across human neocortical development, over 8000 novel lncRNAs were identified. When examining lncRNA expression across 276 individual cells, over 1400 lncRNAs were detected. Interestingly, when the expression levels of individual lncRNAs were analyzed in individual cells, it was found that lncRNAs displayed similar expression levels to protein-coding genes. However, when analyzing expression of the same lncRNAs in bulk tissue samples or within the pooled reads of the 276 individual cells, lncRNA expression levels were detected at much lower levels. This further supports the hypothesis that while lncRNAs are expressed at similar levels to protein-coding genes within individual cells, they display a much higher level of cell type-specific expression.

Numerous studies have now indicated the extensive expression of lncRNAs during all stages of brain development. Global sequencing/profiling experiments have identified thousands of brain-specific lncRNAs. Large-scale efforts, including the Allen Brain Atlas, have begun to examine both the spatial and temporal expression of individual lncRNAs [22, 81]. Additional studies have complemented these large-scale efforts, focusing on more discrete cell populations, including the primary auditory cortex and medial geniculate body [76] or restricted numbers of lncRNAs including, but not limited to, *linc-RBE* [82], *linc-00320* [83], *Dio3os* [84], *Evl1* [85, 86], and *Evl2* [87]. Other studies have observed changes in brain lncRNA expression that are associated with genetic mutants in neurological and psychiatric diseases [88–94] and pharmacological treatments [95, 96] in the brain. Yet despite the large number of lncRNAs that show highly dynamic expression patterns during brain development, many researchers still remain skeptical of their functional importance. A key challenge moving forward is the need to carefully design studies to both address the function of lncRNAs in nervous system development and to identify the mechanisms by which they act.

9.3 LncRNA Function in Nervous System Development

We have previously conducted an extensive review of the role of lncRNAs in regulation of neural development [97]. Here we will briefly discuss the major findings previously reviewed and highlight more recent studies that further demonstrate the importance of lncRNAs in nervous system development.

9.3.1 Lessons Learned from In Vitro Studies

Most large-scale studies of lncRNA function have focused on identifying the regulation of pluripotency states and neural induction. As previously mentioned, numerous lncRNAs display dynamic expression during neural differentiation of ES cells. To identify regulatory role of these lncRNAs, researchers have performed loss of function studies using short hairpin RNA (shRNA)-mediated knockdown and analyzed effects on ES cell differentiation. In particular, inhibition of five lncRNAs resulted in a propensity of the stem cells to adopt a neuroectoderm lineage [98], suggesting a role of these lncRNAs in repressing neural commitment. Additionally, 30% of lncRNAs with selective expression in ES cells interacted with chromatin-modifying proteins, leading the authors to suggest that these lncRNAs function to promote pluripotency through regulation of chromatin architecture [98]. Similarly, further analysis of *lincRNA1230* (*linc1230*) identified that this lncRNA is both necessary and sufficient to repress neural commitment of mouse ES cells [99]. *Linc1230* modulates H3K4me3 accumulation on the promoters of the transcription factors *Pax6* and *Sox1* by interacting with the Trithorax complex component WDR5 [99]. Overexpression of *linc1230* results in reduced WDR5 occupancy and H3K4me3 histone marks at promoters of genes that promote neuronal differentiation, suggesting that *linc1230* inhibits neural induction by sequestering WDR5.

The lncRNA *Tuna* (also known as *megamind* [29]) and 19 additional lncRNAs were identified as regulators of pluripotency through a large-scale RNA-interference screen in mouse ES cells [100]. Interestingly, *Tuna* shows a high degree of sequence homology across vertebrates and is selectively expressed in the nervous system in zebrafish, mouse, and humans. In ES cells, knockdown of *Tuna* results in reduced proliferation, while overexpression of *Tuna* in ES cells resulted in the opposite phenotype, leading to increased proliferation. In differentiating neuronal cultures, loss of *Tuna* expression resulted in reduced expression of neural progenitor markers and genes involved in neural lineage commitment. Consistent with this, knockdown of *megamind* in zebrafish resulted in embryos with small brains and eyes, a phenotype that was rescued by expression of the orthologous zebrafish, human, or mouse isoforms [29]. Further analysis showed that *Tuna* interacts with three RNA-binding proteins (RBPs) [100]. Knockdown of each of these RBPs mimicked the loss of *Tuna* expression within ES cells. Further analyses indicated that *Tuna* expression is required to recruit the RBPs to the promoters of pluripotency factors including *Nanog*, *Sox2*, and *Fgf4*. Chromatin isolation by RNA purification (ChIRP) was used to identify *Tuna*/DNA interactions [101]. ChIRP experiments revealed that *Tuna* was associated with the promoters of pluripotency factors in ES cells [100]. Similarly, the lncRNA *LOC646329* was found to be expressed in radial glia, which functions as neural stem cells during brain development, and in both primary glioblastoma multiforme tumors and

glioblastoma-derived cell lines [78]. Inhibition of *LOC646329* expression reduced the propagation of the tumor cell line, identifying an additional lncRNA that regulates the proliferative capacity of stem cells [78].

Other studies have focused on the function of lncRNAs selectively expressed upon neuronal induction or in regulation of cell fate specification in subventricular zone neural stem cells (SVZ NSCs) [77]. *Six3os* expression is enriched in the stem cells of the SVZ relative to SVZ-derived neural precursors, and its knockdown resulted in fewer neurons and oligodendrocytes and an increase in astrocytes [77]. In contrast, *Dlx1as* also displays robust expression in the SVZ, and inhibition of *Dlx1as* expression inhibited neurogenesis and decreased astrocyte formation, but had no effect on oligodendrocyte production [77]. This phenotype, seen following *Dlx1as* knockdown, may result from altered expression of nearby protein coding genes, as this study observed a decrease in transcript levels of both *Dlx1* and *Dlx2*. Short interfering RNA (siRNA) loss of function was used to analyze the function of four lncRNAs (*Rmst*, *Ak124684*, *Ak091713*, and *Ak055040*) that displayed enriched expression upon neuronal induction of human ES cells. In each case, knockdown of the lncRNA resulted a roughly fivefold decrease in the number of neurons generated, instead promoting oligodendrocyte production [75]. Further analysis of these lncRNAs suggests that they control neuronal fate specification through a variety of different mechanisms. These include regulation of chromatin structure through interactions with SUZ12 (*Ak055040*), regulating expression of the neurogenic miRNAs *miR-125b* and *let-7* (*Ak091713*), interaction with the REST/coREST complex (*Ak124684*), and by functioning as a transcriptional co-regulator, recruiting SOX2 to its transcriptional targets (*RMST*) [75, 102]. Further characterization of the lncRNA *Rmst* has discovered that the miRNA *miR-135a2* is encoded in the last intron of *Rmst* [103]. Recent studies have identified a feedback loop where Lmx1b, in response to Wnt/beta-catenin pathway activation, increases expression of *Rmst/miR-135a2* and *miR-135a2*, which in turn decreases *Wnt1* expression levels. This regulatory circuit thus controls the size of dopaminergic progenitor pool of the midbrain [103–105]. In light of this, it will be interesting to determine the extent of which *Rmst* regulates neural induction independent of *miR-135a2* expression.

lncRNAs have also been identified as regulators of oligodendrocyte specification. While many lncRNAs have been identified as selectively expressed in intermediate neural progenitors prior to oligodendrocyte specification [72], relatively few have been directly identified in oligodendrocyte precursors. In one study, the regulatory function of the antisense transcript *Nkx2.2as* was identified to be a positive regulator of oligodendrocyte specification. *Nkx2.2as* overexpression resulted in an increased number of Nestin + stem cells and a bias toward oligodendrocyte lineage during differentiation of neural stem cells [106]. As *Nkx2.2* is required for oligodendrocyte specification [107], the result of overexpression of *Nkx2.2as* on *Nkx2.2* transcript abundance was examined. It was determined that the sense-antisense pairing of *Nkx2.2as* and *Nkx2.2* stabilized *Nkx2.2* mRNA [106]. However, the effect on Nkx2.2 protein levels remains undetermined. In other studies, the expression of lncRNAs during the controlled differentiation of oligodendrocyte precursor cells (OPC) from neural stem cells was examined. These studies identified that *lnc-OPC* (long noncoding RNA-oligodendrocyte precursor cell) shows highly specific expression in OPCs [108]. Olig2, a transcription factor that is necessary and in some

contexts sufficient, for OPC specification from neural progenitors [109–111], was found to bind the proximal promoter of *Inc-OPC* and induce its expression upon OPC specification [108]. These data implicate lncRNAs in the regulation of both neuronal and glial differentiation.

As many lncRNAs are primate or even human specific [52], studies of such lncRNAs remain limited to cultured cells. Recently, researchers identified the lncRNA *LncND* in a screen for lncRNA transcripts that may function as miRNA sponges during human brain development [112]. lncRNAs, along with transcribed pseudogenes and circular RNAs [58, 113–120], can fine-tune miRNA concentration by sequestering and stabilizing miRNAs within Argonaute protein complexes [121], thereby controlling translation during development [113, 116, 119, 122]. Interestingly, *LncND* is expressed from a genomic locus that is deleted in individuals with certain neurodevelopmental disorders [123–126]. Expression of *LncND* increases during neurogenesis and rapidly drops upon neuronal differentiation [112]. Similarly, *LncND* is expressed at high levels within the ventricular zone of the developing cerebral cortex [112]. In silico analysis predicted 16 putative miR-143-3p seed sites within *LncND*, which were confirmed using luciferase assays [112]. Interaction of *LncND* with AGO2, a component of the RISC complex, further supported the hypothesis that *LncND* functions as a miRNA sponge [112]. Analysis of mRNA transcripts for miR-143-3p binding sites identified putative binding sites of miR-143-3p in the 3' UTRs of both *Notch1* and *Notch2* [112]. Consistent with a role in regulating the Notch signaling pathway, knockdown of *LncND* resulted in decreased Notch pathway activation and a corresponding increase in neurogenesis [112]. Overexpression of *LncND* in cerebral organoids resulted in expansion of the radial glial cell population [112], which phenocopies the effects of increased Notch pathway activation [127–129]. These results suggest that *LncND* functions to sequester and stabilize miR-143-3p within neural progenitors, in order to maintain Notch signaling and prevent premature neuronal differentiation [112].

Many lncRNAs, such as *Meg3* and *Dio3os*, are expressed in the brain and other tissues from imprinted loci [84, 130]. The lncRNA *Meg3* acts as a tumor suppressor, likely by regulating apoptosis and angiogenesis [130]. *Dio3os* is also expressed in the brain from an imprinted locus. In contrast to the usual pattern seen with imprinted lncRNAs and associated protein-coding genes, *Dio3os* and *Dio3* are both expressed from the same chromosome [84, 131]. It will be interesting to determine if *Dio3os* facilitates imprinting of its locus through silencing of the opposite chromosome.

9.3.2 Lessons Learned from In Vivo Analysis of lncRNAs

9.3.2.1 lncRNAs in Retinal Development—One neuronal tissue that has provided a wealth of information regarding lncRNA regulation of nervous system development is the developing retina. The retina serves as a simplified neural tissue that arises from a multipotent pool of progenitor cells capable of generating each of the seven major classes of retinal cell types (six neural—retinal ganglion cells (RGCs), amacrine cells (ACs), bipolar cells (BCs), rod photoreceptors, and cone photoreceptors; one glial cell—Müller glial cells (MG)). SAGE analysis, qRT-PCR, and in situ hybridization experiments on retinal tissue across mouse retinal development indicated the presence and abundance of lncRNAs and

identified cell-type specific expression of many lncRNAs within discrete retinal cell types [49, 132]. Characterization of the function of these lncRNAs in retinal development has subsequently been performed through in vivo gain and loss of function studies [49, 133–136].

The lncRNA *Tug1* was identified in a screen examining genes upregulated after exposure of RPCs to taurine, which induces rod photoreceptor differentiation [133]. Knockdown of *Tug1* resulted in abnormal inner and outer segments of photoreceptors, increased cell death, and an increase in the cone photoreceptor marker PNA, consistent with a role of *Tug1* in promoting rod genesis and inhibiting production of cones [133]. Additional studies of *Tug1* first indicated that *Tug1* regulates cell fate decisions through its interaction with the polycomb repressive complex 2 (PRC2) and through regulation chromatin structure [137]. Interestingly, *Tug1* expression is induced by p53, and loss of *Tug1* expression resulted in an increase of cell-cycle regulator transcript expression, implying that *Tug1* inhibits cell proliferation during cellular damage/stress [133].

The lncRNA *Gomafu*, also known as *RNCR2* or *Miat*, is the most abundantly expressed lncRNA in the developing retina, comprising 0.2% of all polyadenylated transcripts in neonatal mouse retina [49, 135, 138, 139]. Functional studies indicate that *Gomafu* negatively regulates both AC and MG cell differentiation, with loss of function resulting in increased production of ACs and MG [135]. More recently, it was shown that *Gomafu* functions by regulating alternative splicing through interaction with the splicing regulators QKI and SF1 [140]. It will be interesting to determine if *Gomafu*'s role in controlling retinal cell fate specification is mediated by regulation of alternative splicing.

Six3os is a lncRNA that is both divergently transcribed and co-expressed with the homeodomain transcription factor *Six3*. *Six3os* is shown to promote BC specification and inhibit MG development [136]. *Six3os* regulates SIX3 transcriptional activity by acting as a transcriptional scaffold, stabilizing a complex including SIX3, EYA1, and EZH2 and directly regulating expression of SIX3 target genes [136, 141]. In other studies, researchers characterized the expression and function of the natural antisense transcript *Vax2os1*. Overexpression of *Vax2os1* indicates that it functions to maintain the proliferative potential of retinal progenitor cells and prevents premature differentiation of rods [142].

Finally, recent work in the retina has examined functional role of *RNCR4*. *RNCR4* is divergently transcribed from a locus that contains the pre-miRNA cluster miR-183/96/182. The mature miR-183/96/182 and *RNCR4* both display robust expression in photoreceptor cells, beginning at P5 and increasing into adulthood [134]. It was shown that *RNCR4* expression results in increased processing of the pre-miR-183/96/182 to the mature miRNAs by acting as a repressor to the pri-miR-183/96/182 processing inhibitor *Ddx3x* [134]. Increases in the mature miR-183/96/182 expression levels result in aberrant cellular organization of multiple retinal cell types and the appearance of whorls and rosettes in the outer retina as a consequence of premature miR-183/96/182 expression, which in turn disrupts outer limiting membrane formation by altering *Crb1* expression [134]. This suggests that *RNCR4* expression controls the timing of pri-miR-183/96/182 processing to guide retinal histogenesis and outer limiting membrane formation.

9.3.2.2 lncRNAs in Brain Development—As our understanding of genome complexity expands, and tools to manipulate the genome to assess gene function improve, researchers are beginning to assess the requirement of lncRNAs in vivo during brain and nervous system development. In particular, genetic knockout or knockdown experiments are being used to assess the necessity of individual lncRNAs in control of nervous system development. Surprisingly, in many cases in vivo gain and loss of function analysis of individual lncRNAs gives discordant results when compared to in vitro manipulations. Additionally, phenotypes observed following targeted deletions of large regions of DNA that include lncRNA transcript sequence have often been viewed skeptically, due to the potential loss of important cis-regulatory elements of neighboring genes. In this section, we will review our current understanding of the regulation of neural development by lncRNAs in vivo (Sect. 9.3.2.2.1) and highlight the functions attributed to lncRNAs resulting from genetic manipulations of lncRNA expression on nervous system development (Sect. 9.3.2.2.2).

Regulation of Nervous System Development, by lncRNAs In Vivo: Recent studies have identified the neural-specific lncRNA *Pinky* (*Pnky*) as a regulator of neurogenesis in the embryonic and postnatal brain [143]. *Pnky* is expressed at high levels in the ventricular-subventricular zone of the adult brain, a neurogenic niche that is maintained into adulthood [143, 144]. However, *Pnky* expression is downregulated upon activation of the differentiation program of the neural stem cells [143]. Interestingly, when *Pnky* expression is decreased using shRNAs either in vitro or in vivo, the researchers observed an increase in neurogenesis, with a concomitant decrease in the fraction of cells expressing markers of neural stem cells. This likely resulted from an increase in proliferation of transient amplifying cells and decrease in cell death [143]. To further investigate the mechanisms by which *Pnky* functions, the researchers analyzed its protein partners using RNA pulldown followed by mass spectrometry, demonstrating that *Pnky* interacted with PTBP1 [143]. PTBP1 has previously been shown to function as a repressor of neuronal differentiation by both regulating pre-mRNA splicing and by inhibiting expression of the neurogenesis-promoting gene *Ptbp2* [145–150]. Like *Pnky* knockdown, *Ptbp1* knockdown also resulted in expanded production of neurons, regulating a highly overlapping gene set as *Pnky* [143]. The physical interaction between *Pnky* and PTBP1 interaction, the identical phenotype seen following loss of expression, the highly overlapping set of regulated genes, and additional epistasis experiments allowed the researchers to conclude that *Pnky* regulates neurogenesis of ventricular-subventricular zone stem cells through regulation of PTBP1 function [143].

Genetic Loss of Function Studies of lncRNAs in Brain Development: While much of our knowledge about the mechanisms by which lncRNAs regulate neural development stems from in vitro studies, recent efforts have begun to increase the number of genetic models of lncRNA loss of function. Here we will highlight the importance of carefully designed loss of function studies (Fig. 9.2) and compare the results from in vivo genetic manipulations to those seen in cell line-based in vitro studies.

One of the more thoroughly analyzed lncRNAs that regulates brain development is *Evf2* (*Dlx6as1*) [87, 151–153]. *Evf2* is expressed in the Shh-responsive cells of the ventral telencephalon during embryonic development and is transcribed from a region that partially

overlaps ei, one of the two ultra-conserved enhancers (ei + eii) for the neighboring genes *Dlx5* and *Dlx6* [87]. Transcriptional initiation of *Evf2* occurs just 3' to the eii enhancer [87]. Initial in vitro experiments suggested that *Evf2* supplied in trans was required for DLX2 recruitment and activation of the *Dlx5/Dlx6* enhancer sequence, which in turn activated *Dlx5* and *Dlx6* transcription [87]. However, when *Evf2* expression was inhibited by targeted insertion of a premature polyadenylation signal, *Dlx6* expression was actually increased, suggesting that *Evf2* transcription can also function to inhibit *Dlx6* expression [151]. Interestingly, the regulation of *Dlx6* expression by *Evf2* seems to occur in cis, as low levels of ectopic *Evf2* expression fail to rescue *Dlx6* expression in *Evf2*-mutant mice [151]. However, when high levels of *Evf2* are ectopically expressed in *Evf2* mutants, both *Dlx5* and *Dlx6* transcript levels increase, suggesting a trans-acting effect of *Evf2* similar to those that are observed in vitro [87, 151]. Genetic disruption of *Evf2* expression initially resulted in a decrease in the number of hippocampal interneurons, which resolved as the mice matured [151]. However, although the number of interneurons in the adult mice remained similar to wild-type controls, the researchers observed reduced inhibition of the CA1 pyramidal neuron activity [151], the post-synaptic targets of the hippocampal interneurons, implying the presence of a persistent functional defect in these cells.

Other experiments investigating *Evf2* function suggested that loss of *Evf2* expression resulted in a failure to recruit both DLX proteins and the transcriptional repressor MECP2 to the *Dlx5/Dlx6* enhancers [151]. *Evf2* was found to prevent DNA methylation of enhancer ei, suggesting that regulation of ei methylation modulates the binding affinities of DLX1/DLX2 and MECP2 to the enhancer, which in turn regulates *Dlx5/Dlx6* expression [152]. Since *Evf2* is required for recruitment of DLX1/DLX2 to the *Dlx5/Dlx6* enhancer, but does not bind DLX1/DLX2 directly [87, 151], the researchers employed immuno-affinity purification followed by mass spectrometry to identify additional proteins that are part of the *Evf2*-DLX1/DLX2 complex, and which potentially contribute to the *Evf2*-mutant phenotype [153]. These experiments indicated that DLX1 interacts directly with the chromatin remodeling proteins BRG1 and BAF170 in the developing mouse forebrain [153]. DLX1-BRG1 complexes were found to associate with the *Dlx5/Dlx6* enhancers and were enriched in the presence of *Evf2*, suggesting a functional role of the DLX1-BRG1 complex formation in regulation of *Dlx5/Dlx6* expression [153]. Furthermore, BRG1 was found to bind *Evf2* through its RNA-binding domain [153]. Absence of *Evf2* expression decreases DLX1-BRG1 complex formation at the enhancers that control *Dlx5/Dlx6* transcription and also leads to a corresponding decrease in both H3AcK9 and H3AcK18 histone modifications locally [153]. Interestingly, *Evf2* inhibits the ATPase domain of BRG1, suggesting that *Evf2* directs the BRG1-DLX1/DLX2 complex to the *Dlx5/Dlx6* enhancer but that high levels of *Evf2* transcripts within the complex also inhibit the chromatin remodeling activity of BRG1, thus inhibiting *Dlx5/Dlx6* enhancer activity [153].

Much like the approach used to generate *Evf2* knockout animals, *Dlx1as* expression was genetically disrupted through targeted insertion of a premature polyadenylation sequence [154]. Contrary to in vitro reports, where loss of *Dlx1as* resulted in compensatory decrease in *Dlx1* and *Dlx2* expression [77], loss of *Dlx1as* in vivo results in a modest increase *Dlx1* and *Mash1* transcript expression [154]. Since *Dlx1*-mutant mice display profound defects in hippocampal GABAergic interneuron specification [155–157], the researchers next

examined expression of *Gad67*, a marker of GABAergic cells. However, the increase in *Dlx1* expression induced as a consequence of *Dlx1as* loss had no effect on GABAergic interneuron number [154], consistent with previous reports where *Dlx1* overexpression did not induce GABAergic interneuron specification, in sharp contrast to its paralogues *Dlx2* and *Dlx5* [158, 159]. While expression of genes that control GABAergic neuronal specification such as *Dlx1*, *Mash1*, and *Lhx6* is altered within *Dlx1as* brains, no other neurological phenotypes were observed [154]. Instead, slight defects in the alico-chlear commissure were observed in *Dlx1as* mutants [154]. Further investigations will be required to determine if any behavioral phenotypes are observed as a consequence of *Dlx1as* loss of function, akin to those observed for *Evf2*-mutant mice, despite the absence of altered GABAergic interneuron cell number [151].

Recently, a consortium of researchers generated a cohort of targeted deletions of individual mouse lncRNAs to explore their developmental function in vivo [160]. As many lncRNAs overlap protein-coding sequences, the researchers focused on intergenic lncRNAs, so as to investigate phenotypes not attributable to loss of protein-coding gene sequence. Using a combination of cell-based functional assays, RNA-sequencing and computational analyses, the group selected 18 lncRNAs, many with shared homology to human transcript sequences, for targeted deletion in mouse [160]. Of relevance to this review, 12 of the 18 lncRNAs display expression within adult mouse brain or ES cell-derived neural stem cells. Seven of the 12 brain-expressed lncRNAs have human orthologues that display differential expression during human neuronal stem cell differentiation [160].

In order to generate the lncRNA knockouts, the entire lncRNA transcript sequence was replaced with a *lacZ* reporter cassette, allowing a highly sensitive assessment of lncRNA expression patterns using *lacZ/beta-Gal* staining [160]. Targeted inactivation of the lncRNA *Peril*, which is expressed at high levels in mouse ES cells, and shows both temporally and spatially restricted expression within the brain and spinal cord of developing mouse embryos, resulted in reduced viability relative to wild-type or heterozygous littermates [160]. RNA-seq and gene set enrichment analysis (GSEA) of *Peril*^{-/-} brains revealed that genes involved in multiple essential processes including cell cycle regulation and energy metabolism were downregulated [160]. However, the mechanism by which *Peril* loss contributes to lethality remains unknown. The knockout of an additional lncRNA, *Fendrr*, which is expressed at low levels in the developing brain, likewise results in increased lethality. In two separate knockout models, either by gene replacement [160] or insertion of premature polyadenylation signals [161, 162], lethality was observed, as a result of either cardiac [162] or respiratory defects [160]. The role of this lncRNA in brain development, however, remains unexplored.

Interestingly, the locus that encodes the transcription factor *Brn1* (Pou3f3), a well-studied regulator of cortical development [163–165], also contains two lncRNAs (*Pantr1*, also known as *linc-Brn1a*, and *Pantr2*, also known as *linc-Brn1b*) that were both deleted as part of this knockout project [160]. *Pantr1* and *Pantr2* both have conserved human orthologues and were identified as differentially expressed during neural stem cell differentiations [160]. *Pantr1* is transcribed from a region immediately upstream of the transcriptional start site of *Brn1*, and on the opposite strand. Deletion of *Pantr1*, therefore, may also delete portions of

the proximal promoter of *Brn1* and is likely to lead to a decrease in *Brn1* transcription. *Pantr2*, however, is transcribed from a region ~10 kb downstream of the *Brn1* locus, again on the opposite DNA strand. Using the *lacZ* knock-in, it was shown that *Pantr2* is expressed within neural progenitors of the mouse dorsal and ventral telencephalon at E13.5. Expression is maintained within both the subventricular and ventricular zones at E15.5, but more restricted expression is observed in the superior cortical layers by E18.5. Upon deletion of *Pantr2*, *Brn1* transcript and BRN1 protein levels were both decreased by ~50%. *Pantr1* expression, however, was increased [160]. Deletion of *Pantr2* resulted in a reduction in the thickness of all cortical layers, likely the result of reduced proliferation of the intermediate progenitors of the subventricular zone that subsequently give rise to cortical neurons. Examination of the cortex of *Pantr2*^{-/-} mice revealed that a subset of upper-layer cortical neurons were converted to deep layer neurons [160]. This cortical thinning phenotype is similar to what is observed for *Brn1/Brn2* (*Pou3f3/Pou3f2*) double, but not single, mutants [163–165], suggesting that *Pantr2* functions in the specification of upper cortical neuron identity independent of its role in regulating *Brn1* expression [160].

To expand on the preliminary studies of each of the knockout lines, RNA-Seq was conducted at E14.5 and adult stages on brains from knockout and wild-type littermates for the 13 lncRNAs that displayed any brain expression [166]. Interestingly, loss of *Pantr1* or *Pantr2* did not affect *Brn1* expression in whole brains at either time point. Conversely, *Brn1* (*Pou3f3*), *Brn2* (*Pou3f2*), and *Brn4* (*Pou3f4*) all displayed increased expression in *Pantr1* knockout brains at E14.5 [166]. Additionally, of the 13 lncRNA knockout lines studied in these experiments, only five showed significant differences in the expression levels of neighboring gene expression at either the time point [166]. Together, these data further suggest that brain-expressed lncRNAs may function to regulate gene expression both locally in cis but also in trans [166]. Further characterization of each knockout line will be required to determine the specific function of each individual lncRNA.

Some lncRNAs expressed during nervous system development, however, show no or very mild phenotypes following targeted inactivation. Two examples of brain-expressed lncRNAs in which knockout models that fail to produce obvious phenotypes are *Malat1* and *Visc2* [167–170]. Other lncRNA knockouts display only minor phenotypes. The lncRNA *Neat1*, which displays enriched expression in neurons compared to their neural precursors [72], is expressed in a nuclear subdomain known as paraspeckles [171–173]. Paraspeckles are nuclear bodies composed of more than 40 RNA-binding proteins [174]. *Neat1* is required for paraspeckle formation in both in vitro and in vivo studies [171–173, 175, 176]. However, the physiological function of paraspeckle formation is unclear, as mice lacking *Neat1* expression and paraspeckle formation fail to display any clear developmental phenotype [176], with one notable exception. It was recently determined that *Neat1* knockout mice display a stochastic infertility resulting from corpus luteum dysfunction [177, 178]. However, the contribution of *Neat1* and paraspeckle formation to brain development or nervous system diseases such as amyotrophic lateral sclerosis (ALS), where elevated *Neat1* expression is observed during early stages of the disease [179], remains to be determined.

The lncRNA *Gomafu* (also known as *RNCR2* or *Miat*) was previously identified to function in retinal cell fate specification [135], and decrease in *Gomafu* expression is associated with

mRNA splicing defects in schizophrenia [140]. Knockout mice, however, display no gross developmental defects. Instead, behavioral tests performed on *Gomafu* knockouts suggest that these mice display a mild hyperactivity phenotype and enhanced hyperactivity to repeated psychostimulant exposure [180]. Analysis of extracellular dopamine within the nucleus accumbens revealed increased dopamine levels compared to wild-type controls, consistent with the observed hyperactivity [180]. Likewise, schizophrenia patients also exhibit hyperactivity, and *Gomafu* expression is downregulated in postmortem brain samples of schizophrenia patients [140]. However, RNA-Seq analysis of hippocampal cultures from wild-type and *Gomafu* knockout mice revealed only 18 transcripts that displayed differential expression [180]. As *Gomafu* is previously predicted to regulate mRNA splicing through its interactions with the splicing regulators QKI, SF1, and CELF3 [140, 181, 182], alternative splicing of a handful of transcripts was assessed in hippocampal cells of *Gomafu* knockout mice [180]. However, unlike the changes observed in postmortem brain samples from schizophrenia patients, where *Gomafu* showed decreased expression [140], *Gomafu*^{-/-} mice displayed little change in alternative splicing [180].

Despite these studies, our knowledge of the in vivo contributions of lncRNAs to nervous system development remains clouded by emerging discrepancies between in vitro and in vivo results. To further complicate matters, the design of knockout targeting strategies for in vivo loss of function studies can significantly affect interpretations of any phenotypes obtained (Fig. 9.2). For example, three different targeting strategies were used to generate *Malat1* knockout mice. Importantly, while no gross phenotypes were observed in any of the studies [167–169], the effect of *Malat1* loss of function on *Neat1* expression depended on the mechanism by which *Malat1* expression was inhibited. Deletion of either the promoter and proximal 5' transcript sequence or the entire gene body of *Malat1* resulted in an increase in *Neat1* expression [167, 169]. However, insertion of *lacZ* and two premature polyadenylation sequences into the *Malat1* locus resulted in decreased *Neat1* expression [168]. Together, these data indicate the context-dependent sequence requirement for genome architecture. It remains to be determined, however, if *Malat1*-dependent regulation of *Neat1* expression occurs solely by controlling the activity of cis-regulatory elements or whether *Malat1* also regulates *Neat1* transcription in trans.

9.4 Conclusions

With the emergence of vastly improved sequencing technologies, we are beginning to understand the full complexity of the transcriptome. These analyses have revealed that the numbers of lncRNAs have expanded in parallel with the evolutionary increase in brain complexity. Emerging experiments profiling the transcriptomes of nervous system tissue continue to identify many novel lncRNAs. As we continue to identify and characterize the diverse cell types of the brain across development through single-cell RNA-Seq, and continue to explore the complexity of alternative splicing through Capture-seq profiling, we expect that the number of validated lncRNAs will expand dramatically. While considerable effort is now going into investigating the function of these lncRNAs during nervous system development, it is important to keep in mind exactly how these studies are performed. In vitro studies expand the repertoire of mechanistic analyses that we can perform, but results from such studies require in vivo validation, as the lncRNAs are likely functioning in a cell

type- and context-specific manner that is often only imperfectly recapitulated in cultured cells. Furthermore, *in vivo* studies of lncRNA function need to be carefully designed to directly examine the function of the lncRNA transcripts themselves. This is especially important for genetic loss of function studies, where changing the genomic locus that encodes the lncRNA in question may disrupt the activity of important cis-regulatory elements. Additional challenges remain in the design of efforts to address the function of natural-antisense or opposite strand transcripts, due to their genomic proximity to protein-coding genes.

Given the abundance of functions being attributed to lncRNAs, it is especially important to understand their mechanisms of action. Since lncRNAs in many cases function as molecular scaffolds—that bind DNA, RNA, protein, or combinations of these biomolecules—understanding the precise composition of these complexes will be pivotal. However, given the low cellular expression levels and/or scarcity of cell types in which the lncRNAs are expressed, traditional pulldown/mass spectrometry experiments will prove challenging. In any case, recent years have clearly shown that lncRNAs are central to regulation of neuronal differentiation, and our appreciation of their importance will likely grow substantially in the years ahead.

Acknowledgments

B.S.C. was supported by F32EY024201 from the NIH.

References

1. Arendt D, Denes AS, Jekely G, Tessmar-Raible K. The evolution of nervous system centralization. *Philos Trans R Soc Lond Ser B Biol Sci.* 2008; 363(1496):1523–1528. [PubMed: 18192182]
2. Hirth F. On the origin and evolution of the tripartite brain. *Brain Behav Evol.* 2010; 76(1):3–10. [PubMed: 20926853]
3. Galliot B, Quiquand M, Ghila L, de Rosa R, Miljkovic-Licina M, Chera S. Origins of neurogenesis, a cnidarian view. *Dev Biol.* 2009; 332(1):2–24. [PubMed: 19465018]
4. Nakanishi N, Renfer E, Technau U, Rentzsch F. Nervous systems of the sea anemone *Nematostella vectensis* are generated by ectoderm and endoderm and shaped by distinct mechanisms. *Development.* 2012; 139(2):347–357. [PubMed: 22159579]
5. Ohno, S. *Evolution by gene duplication.* Springer; Berlin: 1970.
6. Zhang J. Evolution by gene duplication: an update. *TRENDS Ecol Evol.* 2003; 18(6):292–298.
7. Betizeau M, Cortay V, Patti D, Pfister S, Gautier E, Bellemin-Menard A, Afanassieff M, Huissoud C, Douglas RJ, Kennedy H, Dehay C. Precursor diversity and complexity of lineage relationships in the outer subventricular zone of the primate. *Neuron.* 2013; 80(2):442–457. [PubMed: 24139044]
8. Borrell V, Calegari F. Mechanisms of brain evolution: regulation of neural progenitor cell diversity and cell cycle length. *Neurosci Res.* 2014; 86:14–24. [PubMed: 24786671]
9. Florio M, Huttner WB. Neural progenitors, neurogenesis and the evolution of the neocortex. *Development.* 2014; 141(11):2182–2194. [PubMed: 24866113]
10. Lewitus E, Kelava I, Huttner WB. Conical expansion of the outer subventricular zone and the role of neocortical folding in evolution and development. *Front Hum Neurosci.* 2013; 7:424. [PubMed: 23914167]
11. Lewitus E, Kelava I, Kalinka AT, Tomancak P, Huttner WB. An adaptive threshold in mammalian neocortical evolution. *PLoS Biol.* 2014; 12(11):e1002000. [PubMed: 25405475]
12. Lui JH, Hansen DV, Kriegstein AR. Development and evolution of the human neocortex. *Cell.* 2011; 146(1):18–36. [PubMed: 21729779]

13. Stahl R, Walcher T, De Juan Romero C, Pilz GA, Cappello S, Irmeler M, Sanz-Aquela JM, Beckers J, Blum R, Borrell V, Gotz M. Trnp1 regulates expansion and folding of the mammalian cerebral cortex by control of radial glial fate. *Cell*. 2013; 153(3):535–549. [PubMed: 23622239]
14. Sun T, Hevner RF. Growth and folding of the mammalian cerebral cortex: from molecules to malformations. *Nat Rev Neurosci*. 2014; 15(4):217–232. [PubMed: 24646670]
15. Kaskan, PM., Finlay, BL. Bigger is better: primate brain size in relationship to cognition. In: Falk, D., Gibson, KR., editors. *Evolutionary anatomy of the primate cerebral cortex*. Cambridge University Press; Cambridge: 2001. p. 79-97.
16. Finlay BL, Darlington RB. Linked regularities in the development and evolution of mammalian brains. *Science (New York, NY)*. 1995; 268(5217):1578–1584.
17. Roth G, Dicke U. Evolution of the brain and intelligence. *Trends Cogn Sci*. 2005; 9(5):250–257. [PubMed: 15866152]
18. Jerison, HJ. *Evolution of the brain and intelligence*. 14. Academic; New York: 1973.
19. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhatter R, Gingeras TR, Hubbard TJ, Notredame C, Harrow J, Guigo R. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res*. 2012; 22(9):1775–1789. [PubMed: 22955988]
20. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S, Barnes I, Bignell A, Boychenko V, Hunt T, Kay M, Mukherjee G, Rajan J, Despacio-Reyes G, Saunders G, Steward C, Harte R, Lin M, Howald C, Tanzer A, Derrien T, Chrast J, Walters N, Balasubramanian S, Pei B, Tress M, Rodriguez JM, Ezkurdia I, van Baren J, Brent M, Haussler D, Kellis M, Valencia A, Reymond A, Gerstein M, Guigo R, Hubbard TJ. GENCODE: the reference human genome annotation for the ENCODE project. *Genome Res*. 2012; 22(9):1760–1774. [PubMed: 22955987]
21. Necsulea A, Soumillon M, Warnefors M, Liechti A, Daish T, Zeller U, Baker JC, Grutzner F, Kaessmann H. The evolution of lncRNA repertoires and expression patterns in tetra-pods. *Nature*. 2014; 505(7485):635–640. [PubMed: 24463510]
22. Mercer TR, Dinger ME, Sunkin SM, Mehler MF, Mattick JS. Specific expression of long noncoding RNAs in the mouse brain. *Proc Natl Acad Sci U S A*. 2008; 105(2):716–721. [PubMed: 18184812]
23. Luo H, Sun S, Li P, Bu D, Cao H, Zhao Y. Comprehensive characterization of 10,571 mouse large intergenic noncoding RNAs from whole transcriptome sequencing. *PLoS One*. 2013; 8(8):e70835. [PubMed: 23951020]
24. Ponjavic J, Oliver PL, Lunter G, Ponting CP. Genomic and transcriptional co-localization of protein-coding and long non-coding RNA pairs in the developing brain. *PLoS Genet*. 2009; 5(8):e1000617. [PubMed: 19696892]
25. Francescato M, Vitezic M, Heutink P, Saxena A. Brain-specific noncoding RNAs are likely to originate in repeats and may play a role in up-regulating genes in cis. *Int J Biochem Cell Biol*. 2014; 54:331–337. [PubMed: 24993078]
26. Kaushik K, Leonard VE, Kv S, Lalwani MK, Jalali S, Patowary A, Joshi A, Scaria V, Sivasubbu S. Dynamic expression of long non-coding RNAs (lncRNAs) in adult zebrafish. *PLoS One*. 2013; 8(12):e83616. [PubMed: 24391796]
27. Washietl S, Kellis M, Garber M. Evolutionary dynamics and tissue specificity of human long noncoding RNAs in six mammals. *Genome Res*. 2014; 24(4):616–628. [PubMed: 24429298]
28. Kelley D, Rinn J. Transposable elements reveal a stem cell-specific class of long non-coding RNAs. *Genome Biol*. 2012; 13(11):R107.doi: 10.1186/gb-2012-13-11-r107 [PubMed: 23181609]
29. Ulitsky I, Shkumatava A, Jan CH, Sive H, Bartel DP. Conserved function of lincRNAs in vertebrate embryonic development despite rapid sequence evolution. *Cell*. 2011; 147(7):1537–1550. [PubMed: 22196729]
30. Lipovich L, Hou ZC, Jia H, Sinkler C, McGowen M, Sterner KN, Weckle A, Sugalski AB, Pipes L, Gatti DL, Mason CE, Sherwood CC, Hof PR, Kuzawa CW, Grossman LI, Goodman M, Wildman DE. High-throughput RNA sequencing reveals structural differences of orthologous brain-

- expressed genes between western lowland gorillas and humans. *J Comp Neurol*. 2016; 524(2): 288–308. [PubMed: 26132897]
31. Basu S, Muller F, Sanges R. Examples of sequence conservation analyses capture a subset of mouse long non-coding RNAs sharing homology with fish conserved genomic elements. *BMC Bioinformatics*. 2013; 14(Suppl 7):S14. doi:10.1186/1471-2105-14-S7-S14. Epub 2013 Apr 22.
 32. He Z, Bammann H, Han D, Xie G, Khaitovich P. Conserved expression of lincRNA during human and macaque prefrontal cortex development and maturation. *RNA (New York, NY)*. 2014; 20(7): 1103–1111.
 33. Bird CP, Stranger BE, Liu M, Thomas DJ, Ingle CE, Beazley C, Miller W, Hurles ME, Dermitzakis ET. Fast-evolving noncoding sequences in the human genome. *Genome Biol*. 2007; 8(6):R118. [PubMed: 17578567]
 34. Bush EC, Lahn BT. A genome-wide screen for noncoding elements important in primate evolution. *BMC Evol Biol*. 2008; 8:17. doi: 10.1186/1471-2148-8-17 [PubMed: 18215302]
 35. Pollard KS, Salama SR, Lambert N, Lambot MA, Coppens S, Pedersen JS, Katzman S, King B, Onodera C, Siepel A, Kern AD, Dehay C, Igel H, Ares M Jr, Vanderhaeghen P, Haussler D. An RNA gene expressed during cortical development evolved rapidly in humans. *Nature*. 2006; 443(7108):167–172. [PubMed: 16915236]
 36. Prabhakar S, Visel A, Akiyama JA, Shoukry M, Lewis KD, Holt A, Plajzer-Frick I, Morrison H, Fitzpatrick DR, Afzal V, Pennacchio LA, Rubin EM, Noonan JP. Human-specific gain of function in a developmental enhancer. *Science (New York, NY)*. 2008; 321(5894):1346–1350.
 37. Capra JA, Erwin GD, McKinsey G, Rubenstein JL, Pollard KS. Many human accelerated regions are developmental enhancers. *Philos Trans R Soc Lond Ser B Biol Sci*. 2013; 368(1632): 20130025. [PubMed: 24218637]
 38. Meyer G, Soria JM, Martinez-Galan JR, Martin-Clemente B, Fairen A. Different origins and developmental histories of transient neurons in the marginal zone of the fetal and neonatal rat cortex. *J Comp Neurol*. 1998; 397(4):493–518. [PubMed: 9699912]
 39. Rakic S, Zecevic N. Emerging complexity of layer I in human cerebral cortex. *Cereb Cortex (New York, NY)*. 1991; 2003; 13(10):1072–1083.
 40. Meyer G, Wahle P. The paleocortical ventricle is the origin of reelin-expressing neurons in the marginal zone of the foetal human neocortex. *Eur J Neurosci*. 1999; 11(11):3937–3944. [PubMed: 10583482]
 41. Zecevic N, Rakic P. Development of layer I neurons in the primate cerebral cortex. *J Neurosci*. 2001; 21(15):5607–5619. [PubMed: 11466432]
 42. Pang KC, Frith MC, Mattick JS. Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. *Trends Genet*. 2006; 22(1):1–5. [PubMed: 16290135]
 43. Lewitus E, Huttner WB. Neurodevelopmental LincRNA Microsyteny conservation and mammalian brain size evolution. *PLoS One*. 2015; 10(7):e0131818. [PubMed: 26134977]
 44. Kelava I, Reillo I, Murayama AY, Kalinka AT, Stenzel D, Tomancak P, Matsuzaki F, Lebrand C, Sasaki E, Schwamborn JC, Okano H, Huttner WB, Borrell V. Abundant occurrence of basal radial glia in the subventricular zone of embryonic neocortex of a lissencephalic primate, the common marmoset *Callithrix jacchus*. *Cereb Cortex (New York, NY)*. 2012; 22(2):469–481.
 45. Kelava I, Lewitus E, Huttner WB. The secondary loss of gyrencephaly as an example of evolutionary phenotypical reversal. *Front Neuroanat*. 2013; 7:16. [PubMed: 23805079]
 46. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K, Bajic VB, Brenner SE, Batalov S, Forrest AR, Zavolan M, Davis MJ, Wilming LG, Aidinis V, Allen JE, Ambesi-Impombato A, Apweiler R, Aturaliya RN, Bailey TL, Bansal M, Baxter L, Beisel KW, Bersano T, Bono H, Chalk AM, Chiu KP, Choudhary V, Christoffels A, Clutterbuck DR, Crowe ML, Dalla E, Dalrymple BP, de Bono B, Della Gatta G, di Bernardo D, Down T, Engstrom P, Fagiolini M, Faulkner G, Fletcher CF, Fukushima T, Furuno M, Futaki S, Gariboldi M, Georgii-Hemming P, Gingeras TR, Gojobori T, Green RE, Gustincich S, Harbers M, Hayashi Y, Hensch TK, Hirokawa N, Hill D, Huminiecki L, Iacono M, Ikeo K, Iwama A, Ishikawa T, Jakt M, Kanapin A, Katoh M, Kawasawa Y, Kelso J, Kitamura H, Kitano H, Kollias G, Krishnan SP, Kruger A, Kummerfeld SK, Kurochkin IV, Lareau LF, Lazarevic D, Lipovich L, Liu J, Liuni S, McWilliam S, Madan Babu M, Madera M, Marchionni L, Matsuda H,

Matsuzawa S, Miki H, Mignone F, Miyake S, Morris K, Mottagui-Tabar S, Mulder N, Nakano N, Nakauchi H, Ng P, Nilsson R, Nishiguchi S, Nishikawa S, Nori F, Ohara O, Okazaki Y, Orlando V, Pang KC, Pavan WJ, Pavesi G, Pesole G, Petrovsky N, Piazza S, Reed J, Reid JF, Ring BZ, Ringwald M, Rost B, Ruan Y, Salzberg SL, Sandelin A, Schneider C, Schonbach C, Sekiguchi K, Semple CA, Seno S, Sessa L, Sheng Y, Shibata Y, Shimada H, Shimada K, Silva D, Sinclair B, Sperling S, Stupka E, Sugiura K, Sultana R, Takenaka Y, Taki K, Tammoja K, Tan SL, Tang S, Taylor MS, Tegner J, Teichmann SA, Ueda HR, van Nimwegen E, Verardo R, Wei CL, Yagi K, Yamanishi H, Zabarovsky E, Zhu S, Zimmer A, Hide W, Bult C, Grimmond SM, Teasdale RD, Liu ET, Brusic V, Quackenbush J, Wahlestedt C, Mattick JS, Hume DA, Kai C, Sasaki D, Tomaru Y, Fukuda S, Kanamori-Katayama M, Suzuki M, Aoki J, Arakawa T, Iida J, Imamura K, Itoh M, Kato T, Kawaji H, Kawagashira N, Kawashima T, Kojima M, Kondo S, Konno H, Nakano K, Ninomiya N, Nishio T, Okada M, Plessy C, Shibata K, Shiraki T, Suzuki S, Tagami M, Waki K, Watahiki A, Okamura-Oho Y, Suzuki H, Kawai J, Hayashizaki Y. FANTOM Consortium & RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group). The transcriptional landscape of the mammalian genome. *Science (New York, NY)*. 2005; 309(5740):1559–1563.

47. Xie C, Yuan J, Li H, Li M, Zhao G, Bu D, Zhu W, Wu W, Chen R, Zhao Y. NONCODEv4: exploring the world of long non-coding RNA genes. *Nucleic Acids Res*. 2014; 42:D98–103. [PubMed: 24285305]
48. Lv J, Liu H, Huang Z, Su J, He H, Xiu Y, Zhang Y, Wu Q. Long non-coding RNA identification over mouse brain development by integrative modeling of chromatin and genomic features. *Nucleic Acids Res*. 2013; 41(22):10044–10061. [PubMed: 24038472]
49. Blackshaw S, Harpavat S, Trimarchi J, Cai L, Huang H, Kuo WP, Weber G, Lee K, Fraioli RE, Cho SH, Yung R, Asch E, Ohno-Machado L, Wong WH, Cepko CL. Genomic analysis of mouse retinal development. *PLoS Biol*. 2004; 2(9):E247. [PubMed: 15226823]
50. Aprea J, Prenninger S, Dori M, Ghosh T, Monasor LS, Wessendorf E, Zocher S, Massalini S, Alexopoulou D, Lesche M, Dahl A, Groszer M, Hiller M, Calegari F. Transcriptome sequencing during mouse brain development identifies long non-coding RNAs functionally involved in neurogenic commitment. *EMBO J*. 2013; 32(24):3145–3160. [PubMed: 24240175]
51. Mehler MF, Mattick JS. Noncoding RNAs and RNA editing in brain development, functional diversification, and neurological disease. *Physiol Rev*. 2007; 87(3):799–823. [PubMed: 17615389]
52. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. *Genes Dev*. 2011; 25(18):1915–1927. [PubMed: 21890647]
53. Jorgenson LA, Newsome WT, Anderson DJ, Bargmann CI, Brown EN, Deisseroth K, Donoghue JP, Hudson KL, Ling GS, MacLeish PR, Marder E, Normann RA, Sanes JR, Schnitzer MJ, Sejnowski TJ, Tank DW, Tsien RY, Ugurbil K, Wingfield JC. The BRAIN initiative: developing technology to catalyse neuroscience discovery. *Philos Trans R Soc Lond Ser B Biol Sci*. 2015; 370(1668)doi: 10.1098/rstb.2014.0164
54. Zhang K, Huang K, Luo Y, Li S. Identification and functional analysis of long non-coding RNAs in mouse cleavage stage embryonic development based on single cell transcriptome data. *BMC Genomics*. 2014; 15:845.doi: 10.1186/1471-2164-15-845 [PubMed: 25277336]
55. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE. Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA (New York, NY)*. 2013; 19(2):141–157.
56. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. *PLoS One*. 2012; 7(2):e30733. [PubMed: 22319583]
57. Barrett SP, Salzman J. Circular RNAs: analysis, expression and potential functions. *Development*. 2016; 143(11):1838–1847. [PubMed: 27246710]
58. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F, Rajewsky N. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature*. 2013; 495(7441):333–338. [PubMed: 23446348]

59. Bussotti G, Leonardi T, Clark MB, Mercer TR, Crawford J, Malquori L, Notredame C, Dinger ME, Mattick JS, Enright AJ. Improved definition of the mouse transcriptome via targeted RNA sequencing. *Genome Res.* 2016; 26(5):705–716. [PubMed: 27197243]
60. Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Trapnell C, Jeddelloh JA, Mattick JS, Rinn JL. Targeted RNA sequencing reveals the deep complexity of the human transcriptome. *Nat Biotechnol.* 2011; 30(1):99–104. [PubMed: 22081020]
61. Clark MB, Mercer TR, Bussotti G, Leonardi T, Haynes KR, Crawford J, Brunck ME, Cao KA, Thomas GP, Chen WY, Taft RJ, Nielsen LK, Enright AJ, Mattick JS, Dinger ME. Quantitative gene profiling of long noncoding RNAs with targeted RNA sequencing. *Nat Methods.* 2015; 12(4):339–342. [PubMed: 25751143]
62. Mercer TR, Clark MB, Crawford J, Brunck ME, Gerhardt DJ, Taft RJ, Nielsen LK, Dinger ME, Mattick JS. Targeted sequencing for gene discovery and quantification using RNA Capture-Seq. *Nat Protoc.* 2014; 9(5):989–1009. [PubMed: 24705597]
63. Dinger ME, Amaral PP, Mercer TR, Pang KC, Bruce SJ, Gardiner BB, Askarian-Amiri ME, Ru K, Solda G, Simons C, Sunkin SM, Crowe ML, Grimmond SM, Perkins AC, Mattick JS. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. *Genome Res.* 2008; 18(9):1433–1445. [PubMed: 18562676]
64. Bruce SJ, Gardiner BB, Burke LJ, Gongora MM, Grimmond SM, Perkins AC. Dynamic transcription programs during ES cell differentiation towards mesoderm in serum versus serum-free BMP4 culture. *BMC Genomics.* 2007; 8:365. [PubMed: 17925037]
65. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. *Science (New York, NY).* 2002; 298(5593):601–604.
66. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. “Stemness”: transcriptional profiling of embryonic and adult stem cells. *Science (New York, NY).* 2002; 298(5593):597–600.
67. Meshorer E, Yellajoshula D, George E, Scambler PJ, Brown DT, Misteli T. Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic stem cells. *Dev Cell.* 2006; 10(1):105–116. [PubMed: 16399082]
68. Meshorer E, Misteli T. Chromatin in pluripotent embryonic stem cells and differentiation. *Nat Rev Mol Cell Biol.* 2006; 7(7):540–546. [PubMed: 16723974]
69. Gaspar-Maia A, Alajem A, Polesso F, Sridharan R, Mason MJ, Heidersbach A, Ramalho-Santos J, McManus MT, Plath K, Meshorer E, Ramalho-Santos M. Chd1 regulates open chromatin and pluripotency of embryonic stem cells. *Nature.* 2009; 460(7257):863–868. [PubMed: 19587682]
70. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature.* 2009; 458(7235):223–227. [PubMed: 19182780]
71. Guttman M, Garber M, Levin JZ, Donaghey J, Robinson J, Adiconis X, Fan L, Koziol MJ, Gnirke A, Nusbaum C, Rinn JL, Lander ES, Regev A. Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. *Nat Biotechnol.* 2010; 28(5):503–510. [PubMed: 20436462]
72. Mercer TR, Qureshi IA, Gokhan S, Dinger ME, Li G, Mattick JS, Mehler MF. Long noncoding RNAs in neuronal-glia fate specification and oligodendrocyte lineage maturation. *BMC Neurosci.* 2010; 11:14. doi: 10.1186/1471-2202-11-14 [PubMed: 20137068]
73. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. *Curr Biol.* 2002; 12(9):735–739. [PubMed: 12007417]
74. Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. *Mol Cell.* 2007; 27(3):435–448. [PubMed: 17679093]
75. Ng SY, Johnson R, Stanton LW. Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. *EMBO J.* 2012; 31(3):522–533. [PubMed: 22193719]
76. Guo Y, Zhang P, Sheng Q, Zhao S, Hackett TA. lncRNA expression in the auditory forebrain during postnatal development. *Gene.* 2016; 593(1):201–216. [PubMed: 27544636]

77. Ramos AD, Diaz A, Nellore A, Delgado RN, Park KY, Gonzales-Roybal G, Oldham MC, Song JS, Lim DA. Integration of genome-wide approaches identifies lncRNAs of adult neural stem cells and their progeny in vivo. *Cell Stem Cell*. 2013; 12(5):616–628. [PubMed: 23583100]
78. Liu SJ, Nowakowski TJ, Pollen AA, Lui JH, Horlbeck MA, Attenello FJ, He D, Weissman JS, Kriegstein AR, Diaz AA, Lim DA. Single-cell analysis of long non-coding RNAs in the developing human neocortex. *Genome Biol*. 2016; 17:67. doi: 10.1186/s13059-016-0932-1 [PubMed: 27081004]
79. Rapicavoli NA, Blackshaw S. New meaning in the message: noncoding RNAs and their role in retinal development. *Dev Dyn*. 2009; 238(9):2103–2114. [PubMed: 19191220]
80. Molyneaux BJ, Goff LA, Brettler AC, Chen HH, Brown JR, Hrvatin S, Rinn JL, Arlotta P. DeCoN: genome-wide analysis of in vivo transcriptional dynamics during pyramidal neuron fate selection in neocortex. *Neuron*. 2015; 85(2):275–288. [PubMed: 25556833]
81. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, Chen L, Chen L, Chen TM, Chin MC, Chong J, Crook BE, Czaplinska A, Dang CN, Datta S, Dee NR, Desaki AL, Desta T, Diep E, Dolbeare TA, Donelan MJ, Dong HW, Dougherty JG, Duncan BJ, Ebbert AJ, Eichele G, Estin LK, Faber C, Facer BA, Fields R, Fischer SR, Fliss TP, Frensley C, Gates SN, Glattfelder KJ, Halverson KR, Hart MR, Hohmann JG, Howell MP, Jeung DP, Johnson RA, Karr PT, Kawal R, Kidney JM, Knapik RH, Kuan CL, Lake JH, Laramie AR, Larsen KD, Lau C, Lemon TA, Liang AJ, Liu Y, Luong LT, Michaels J, Morgan JJ, Morgan RJ, Mortrud MT, Mosqueda NF, Ng LL, Ng R, Orta GJ, Overly CC, Pak TH, Parry SE, Pathak SD, Pearson OC, Puchalski RB, Riley ZL, Rockett HR, Rowland SA, Royall JJ, Ruiz MJ, Sarno NR, Schaffnit K, Shapovalova NV, Sivasay T, Slaughterbeck CR, Smith SC, Smith KA, Smith BI, Sodt AJ, Stewart NN, Stumpf KR, Sunkin SM, Sutram M, Tam A, Teemer CD, Thaller C, Thompson CL, Varnam LR, Visel A, Whitlock RM, Wohnoutka PE, Wolkey CK, Wong VY, Wood M, Yaylaoglu MB, Young RC, Youngstrom BL, Yuan XF, Zhang B, Zwingman TA, Jones AR. Genome-wide atlas of gene expression in the adult mouse brain. *Nature*. 2007; 445(7124):168–176. [PubMed: 17151600]
82. Kour S, Rath PC. Age-dependent differential expression profile of a novel intergenic long noncoding RNA in rat brain. *Int J Dev Neurosci*. 2015; 47(Pt B):286–297. [PubMed: 26390953]
83. Mills JD, Chen J, Kim WS, Waters PD, Prabowo AS, Aronica E, Halliday GM, Janitz M. Long intervening non-coding RNA 00320 is human brain-specific and highly expressed in the cortical white matter. *Neurogenetics*. 2015; 16(3):201–213. [PubMed: 25819921]
84. Dietz WH, Masterson K, Sittig LJ, Redei EE, Herzing LB. Imprinting and expression of Dio3os mirrors Dio3 in rat. *Front Genet*. 2012; 3:279. [PubMed: 23230449]
85. Kohtz JD, Baker DP, Corte G, Fishell G. Regionalization within the mammalian telencephalon is mediated by changes in responsiveness to sonic hedgehog. *Development*. 1998; 125(24):5079–5089. [PubMed: 9811591]
86. Kohtz JD, Fishell G. Developmental regulation of EVF-1, a novel non-coding RNA transcribed upstream of the mouse *Dlx6* gene. *Gene Expr Patterns*. 2004; 4(4):407–412. [PubMed: 15183307]
87. Feng J, Bi C, Clark BS, Mady R, Shah P, Kohtz JD. The *Evf-2* noncoding RNA is transcribed from the *Dlx-5/6* ultraconserved region and functions as a *Dlx-2* transcriptional coactivator. *Genes Dev*. 2006; 20(11):1470–1484. [PubMed: 16705037]
88. Davis CJ, Taishi P, Honn KA, Koberstein JN, Krueger JM. P2X7 receptors in body temperature, locomotor activity, and brain mRNA and lncRNA responses to sleep deprivation. *Am J Physiol Regul Integr Comp Physiol*. 2016; 311(6):R1004–R1012. DOI: 10.1152/ajpregu.00167.2016 [PubMed: 27707719]
89. Zhong J, Jiang L, Cheng C, Huang Z, Zhang H, Liu H, He J, Cao F, Peng J, Jiang Y, Sun X. Altered expression of long non-coding RNA and mRNA in mouse cortex after traumatic brain injury. *Brain Res*. 2016; 1646:589–600. [PubMed: 27380725]
90. Jiang H, Good DJ. A molecular conundrum involving hypothalamic responses to and roles of long non-coding RNAs following food deprivation. *Mol Cell Endocrinol*. 2016; 438:52–60. [PubMed: 2755291]
91. D'haene E, Jacobs EZ, Volders PJ, De Meyer T, Menten B, Vergult S. Identification of long non-coding RNAs involved in neuronal development and intellectual disability. *Sci Rep*. 2016; 6:28396. [PubMed: 27319317]

92. Chen R, Liu L, Xiao M, Wang F, Lin X. Microarray expression profile analysis of long noncoding RNAs in premature brain injury: a novel point of view. *Neuroscience*. 2016; 319:123–133. [PubMed: 26812036]
93. Kraus TF, Haider M, Spanner J, Steinmaurer M, Dietinger V, Kretschmar HA. Altered long noncoding RNA expression precedes the course of Parkinson's disease—a preliminary report. *Mol Neurobiol*. 2016; 54(4):2869–2877. [PubMed: 27021022]
94. Faedo A, Quinn JC, Stoney P, Long JE, Dye C, Zollo M, Rubenstein JL, Price DJ, Bulfone A. Identification and characterization of a novel transcript down-regulated in *Dlx1/Dlx2* and up-regulated in *Pax6* mutant telencephalon. *Dev Dyn*. 2004; 231(3):614–620. [PubMed: 15376329]
95. Kour S, Rath PC. All-trans retinoic acid induces expression of a novel Intergenic long noncoding RNA in adult rat primary hippocampal neurons. *J Mol Neurosci*. 2016; 58(2):266–276. [PubMed: 26572536]
96. Chen X, Zhou X, Lu D, Yang X, Zhou Z, Chen X, Chen Y, He W, Feng X. Aberrantly expressed long noncoding RNAs are involved in sevoflurane-induced developing hippocampal neuronal apoptosis: a microarray related study. *Metab Brain Dis*. 2016; 31(5):1031–1040. [PubMed: 27234990]
97. Clark BS, Blackshaw S. Long non-coding RNA-dependent transcriptional regulation in neuronal development and disease. *Front Genet*. 2014; 5:164. [PubMed: 24936207]
98. Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang X, Amit I, Meissner A, Regev A, Rinn JL, Root DE, Lander ES. lincRNAs act in the circuitry controlling pluripotency and differentiation. *Nature*. 2011; 477(7364):295–300. [PubMed: 21874018]
99. Wang C, Li G, Wu Y, Xi J, Kang J. LincRNA1230 inhibits the differentiation of mouse ES cells towards neural progenitors. *Sci China Life Sci*. 2016; 59(5):443–454. [PubMed: 26920680]
100. Lin N, Chang KY, Li Z, Gates K, Rana ZA, Dang J, Zhang D, Han T, Yang CS, Cunningham TJ, Head SR, Duester G, Dong PD, Rana TM. An evolutionarily conserved long noncoding RNA TUNA controls pluripotency and neural lineage commitment. *Mol Cell*. 2014; 53(6):1005–1019. [PubMed: 24530304]
101. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. *Mol Cell*. 2011; 44(4):667–678. [PubMed: 21963238]
102. Ng SY, Bogu GK, Soh BS, Stanton LW. The long noncoding RNA RMST interacts with SOX2 to regulate neurogenesis. *Mol Cell*. 2013; 51(3):349–359. [PubMed: 23932716]
103. Anderegg A, Lin HP, Chen JA, Caronia-Brown G, Cherepanova N, Yun B, Joksimovic M, Rock J, Harfe BD, Johnson R, Awatramani R. An *Lmx1b*-miR135a2 regulatory circuit modulates *Wnt1/Wnt* signaling and determines the size of the midbrain dopaminergic progenitor pool. *PLoS Genet*. 2013; 9(12):e1003973. [PubMed: 24348261]
104. Anderegg A, Awatramani R. k the size of the midbrain and the dopaminergic progenitor pool. *Neurogenesis (Austin, TX)*. 2015; 2(1):e998101.
105. Caronia-Brown G, Anderegg A, Awatramani R. Expression and functional analysis of the *Wnt/beta-catenin* induced *mir-135a-2* locus in embryonic forebrain development. *Neural Dev*. 2016; 11:9.doi: 10.1186/s13064-016-0065-y [PubMed: 27048518]
106. Tochtani S, Hayashizaki Y. *Nkx2.2* antisense RNA overexpression enhanced oligo-dendrocytic differentiation. *Biochem Biophys Res Commun*. 2008; 372(4):691–696. [PubMed: 18538132]
107. Qi Y, Cai J, Wu Y, Wu R, Lee J, Fu H, Rao M, Sussel L, Rubenstein J, Qiu M. Control of oligodendrocyte differentiation by the *Nkx2.2* homeodomain transcription factor. *Development*. 2001; 128(14):2723–2733. [PubMed: 11526078]
108. Dong X, Chen K, Cuevas-Diaz Duran R, You Y, Sloan SA, Zhang Y, Zong S, Cao Q, Barres BA, Wu JQ. Comprehensive identification of long non-coding RNAs in purified cell types from the brain reveals functional LncRNA in OPC fate determination. *PLoS Genet*. 2015; 11(12):e1005669. [PubMed: 26683846]
109. Yang N, Zuchero JB, Ahlenius H, Marro S, Ng YH, Vierbuchen T, Hawkins JS, Geissler R, Barres BA, Wernig M. Generation of oligodendroglial cells by direct lineage conversion. *Nat Biotechnol*. 2013; 31(5):434–439. [PubMed: 23584610]

110. Lu QR, Sun T, Zhu Z, Ma N, Garcia M, Stiles CD, Rowitch DH. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. *Cell*. 2002; 109(1):75–86. [PubMed: 11955448]
111. Zhou Q, Choi G, Anderson DJ. The bHLH transcription factor Olig2 promotes oligo-dendrocyte differentiation in collaboration with Nkx2.2. *Neuron*. 2001; 31(5):791–807. [PubMed: 11567617]
112. Rani N, Nowakowski TJ, Zhou H, Godshalk SE, Lisi V, Kriegstein AR, Kosik KS. A primate lncRNA mediates notch signaling during neuronal development by sequestering miRNA. *Neuron*. 2016; 90(6):1174–1188. [PubMed: 27263970]
113. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. *Cell*. 2011; 147(2):358–369. [PubMed: 22000014]
114. Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. *Curr Biol*. 2010; 20(19):R858–R861. [PubMed: 20937476]
115. Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. *Cancer Res*. 2013; 73(18):5609–5612. [PubMed: 24014594]
116. Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, Lu L, Liu C, Yi JS, Zhang H, Min W, Bennett AM, Gregory RI, Ding Y, Huang Y. The imprinted H19 lncRNA antagonizes let-7 microRNAs. *Mol Cell*. 2013; 52(1):101–112. [PubMed: 24055342]
117. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, Lieberman J, Rigoutsos I, Pandolfi PP. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. *Cell*. 2011; 147(2):344–357. [PubMed: 22000013]
118. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. *Nature*. 2014; 505(7483):344–352. [PubMed: 24429633]
119. Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, Wu M, Xiong J, Guo X, Liu H. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. *Dev Cell*. 2013; 25(1):69–80. [PubMed: 23541921]
120. Zhang Z, Zhu Z, Watabe K, Zhang X, Bai C, Xu M, Wu F, Mo YY. Negative regulation of lncRNA GAS5 by miR-21. *Cell Death Differ*. 2013; 20(11):1558–1568. [PubMed: 23933812]
121. Bail S, Swerdel M, Liu H, Jiao X, Goff LA, Hart RP, Kiledjian M. Differential regulation of microRNA stability. *RNA (New York, NY)*. 2010; 16(5):1032–1039.
122. Legnini I, Morlando M, Mangiavacchi A, Fatica A, Bozzoni I. A feedforward regulatory loop between HuR and the long noncoding RNA linc-MD1 controls early phases of myogenesis. *Mol Cell*. 2014; 53(3):506–514. [PubMed: 24440503]
123. Stevens SJ, van Ravenswaaij-Arts CM, Janssen JW, Klein Wassink-Ruiter JS, van Essen AJ, Dijkhuizen T, van Rheenen J, Heuts-Vijgen R, Stegmann AP, Smeets EE, Engelen JJ. MYT1L is a candidate gene for intellectual disability in patients with 2p25.3 (2pter) deletions. *Am J Med Genet A*. 2011; 155A(11):2739–2745. [PubMed: 21990140]
124. Rio M, Royer G, Gobin S, de Blois MC, Ozilou C, Bernheim A, Nizon M, Munnich A, Bonnefont JP, Romana S, Vekemans M, Turleau C, Malan V. Monozygotic twins discordant for submicroscopic chromosomal anomalies in 2p25.3 region detected by array CGH. *Clin Genet*. 2013; 84(1):31–36. [PubMed: 23061379]
125. Doco-Fenzy M, Leroy C, Schneider A, Petit F, Delrue MA, Andrieux J, Perrin-Sabourin L, Landais E, Aboura A, Puechberty J, Girard M, Tournaire M, Sanchez E, Rooryck C, Ameil A, Goossens M, Jonveaux P, Lefort G, Taine L, Cailley D, Gaillard D, Leheup B, Sarda P, Genevieve D. Early-onset obesity and paternal 2pter deletion encompassing the ACP1, TMEM18, and MYT1L genes. *Eur J Hum Genet*. 2014; 22(4):471–479. [PubMed: 24129437]
126. Bonaglia MC, Giorda R, Zanini S. A new patient with a terminal de novo 2p25.3 deletion of 1.9 Mb associated with early-onset of obesity, intellectual disabilities and hyperkinetic disorder. *Mol Cytogenet*. 2014; 7:53.doi: 10.1186/1755-8166-7-53 [PubMed: 25126114]
127. Gaiano N, Nye JS, Fishell G. Radial glial identity is promoted by Notch1 signaling in the murine forebrain. *Neuron*. 2000; 26(2):395–404. [PubMed: 10839358]
128. Shimojo H, Ohtsuka T, Kageyama R. Oscillations in notch signaling regulate maintenance of neural progenitors. *Neuron*. 2008; 58(1):52–64. [PubMed: 18400163]

129. Yoon KJ, Koo BK, Im SK, Jeong HW, Ghim J, Kwon MC, Moon JS, Miyata T, Kong YY. Mind bomb 1-expressing intermediate progenitors generate notch signaling to maintain radial glial cells. *Neuron*. 2008; 58(4):519–531. [PubMed: 18498734]
130. Gordon FE, Nutt CL, Cheunsuchon P, Nakayama Y, Provencher KA, Rice KA, Zhou Y, Zhang X, Klibanski A. Increased expression of angiogenic genes in the brains of mouse meg3-null embryos. *Endocrinology*. 2010; 151(6):2443–2452. [PubMed: 20392836]
131. Sun S, Payer B, Namekawa S, An JY, Press W, Catalan-Dibene J, Sunwoo H, Lee JT. Xist imprinting is promoted by the hemizygous (unpaired) state in the male germ line. *Proc Natl Acad Sci U S A*. 2015; 112(47):14415–14422. [PubMed: 26489649]
132. Alfano G, Vitiello C, Caccioppoli C, Caramico T, Carola A, Szego MJ, McInnes RR, Auricchio A, Banfi S. Natural antisense transcripts associated with genes involved in eye development. *Hum Mol Genet*. 2005; 14(7):913–923. [PubMed: 15703187]
133. Young TL, Matsuda T, Cepko CL. The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina. *Curr Biol*. 2005; 15(6):501–512. [PubMed: 15797018]
134. Krol J, Krol I, Alvarez CP, Fiscella M, Hierlemann A, Roska B, Filipowicz W. A network comprising short and long noncoding RNAs and RNA helicase controls mouse retina architecture. *Nat Commun*. 2015; 6:7305. [PubMed: 26041499]
135. Rapicavoli NA, Poth EM, Blackshaw S. The long noncoding RNA RNCR2 directs mouse retinal cell specification. *BMC Dev Biol*. 2010; 10:49.doi: 10.1186/1471-213X-10-49 [PubMed: 20459797]
136. Rapicavoli NA, Poth EM, Zhu H, Blackshaw S. The long noncoding RNA Six3OS acts in trans to regulate retinal development by modulating Six3 activity. *Neural Dev*. 2011; 6:32.doi: 10.1186/1749-8104-6-32 [PubMed: 21936910]
137. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, Regev A, Lander ES, Rinn JL. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. *Proc Natl Acad Sci U S A*. 2009; 106(28):11667–11672. [PubMed: 19571010]
138. Ishii N, Ozaki K, Sato H, Mizuno H, Saito S, Takahashi A, Miyamoto Y, Ikegawa S, Kamatani N, Hori M, Saito S, Nakamura Y, Tanaka T. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. *J Hum Genet*. 2006; 51(12):1087–1099. [PubMed: 17066261]
139. Sone M, Hayashi T, Tarui H, Agata K, Takeichi M, Nakagawa S. The mRNA-like noncoding RNA Gomafu constitutes a novel nuclear domain in a subset of neurons. *J Cell Sci*. 2007; 120(Pt 15):2498–2506. [PubMed: 17623775]
140. Barry G, Briggs JA, Vanichkina DP, Poth EM, Beveridge NJ, Ratnu VS, Nayler SP, Nones K, Hu J, Bredy TW, Nakagawa S, Rigo F, Taft RJ, Cairns MJ, Blackshaw S, Wolvetang EJ, Mattick JS. The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing. *Mol Psychiatry*. 2014; 19(4):486–494. [PubMed: 23628989]
141. Zhao J, Ohsumi TK, Kung JT, Ogawa Y, Grau DJ, Sarma K, Song JJ, Kingston RE, Borowsky M, Lee JT. Genome-wide identification of polycomb-associated RNAs by RIP-seq. *Mol Cell*. 2010; 40(6):939–953. [PubMed: 21172659]
142. Meola N, Pizzo M, Alfano G, Surace EM, Banfi S. The long noncoding RNA Vax2os1 controls the cell cycle progression of photoreceptor progenitors in the mouse retina. *RNA (New York, NY)*. 2012; 18(1):111–123.
143. Ramos AD, Andersen RE, Liu SJ, Nowakowski TJ, Hong SJ, Gertz CC, Salinas RD, Zarabi H, Kriegstein AR, Lim DA. The long noncoding RNA Pnky regulates neuronal differentiation of embryonic and postnatal neural stem cells. *Cell Stem Cell*. 2015; 16(4):439–447. [PubMed: 25800779]
144. Kriegstein A, Alvarez-Buylla A. The glial nature of embryonic and adult neural stem cells. *Annu Rev Neurosci*. 2009; 32:149–184. [PubMed: 19555289]
145. Zheng S, Gray EE, Chawla G, Porse BT, O'Dell TJ, Black DL. PSD-95 is post-transcriptionally repressed during early neural development by PTBP1 and PTBP2. *Nat Neurosci*. 2012; 15(3):381–388. S1. [PubMed: 22246437]

146. Yap K, Lim ZQ, Khandelia P, Friedman B, Makeyev EV. Coordinated regulation of neuronal mRNA steady-state levels through developmentally controlled intron retention. *Genes Dev.* 2012; 26(11):1209–1223. [PubMed: 22661231]
147. Keppetipola N, Sharma S, Li Q, Black DL. Neuronal regulation of pre-mRNA splicing by polypyrimidine tract binding proteins, PTBP1 and PTBP2. *Crit Rev Biochem Mol Biol.* 2012; 47(4):360–378. [PubMed: 22655688]
148. Shibasaki T, Tokunaga A, Sakamoto R, Sagara H, Noguchi S, Sasaoka T, Yoshida N. PTB deficiency causes the loss of adherens junctions in the dorsal telencephalon and leads to lethal hydrocephalus. *Cereb Cortex (New York, NY: 1991).* 2013; 23(8):1824–1835.
149. Boutz PL, Stoilov P, Li Q, Lin CH, Chawla G, Ostrow K, Shiue L, Ares M Jr, Black DL. A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. *Genes Dev.* 2007; 21(13):1636–1652. [PubMed: 17606642]
150. Licatalosi DD, Yano M, Fak JJ, Mele A, Grabinski SE, Zhang C, Darnell RB. Ptbp2 represses adult-specific splicing to regulate the generation of neuronal precursors in the embryonic brain. *Genes Dev.* 2012; 26(14):1626–1642. [PubMed: 22802532]
151. Bond AM, Vangompel MJ, Sametsky EA, Clark MF, Savage JC, Disterhoft JF, Kohtz JD. Balanced gene regulation by an embryonic brain ncRNA is critical for adult hippocampal GABA circuitry. *Nat Neurosci.* 2009; 12(8):1020–1027. [PubMed: 19620975]
152. Berghoff EG, Clark MF, Chen S, Cajigas I, Leib DE, Kohtz JD. Evf2 (Dlx6as) lncRNA regulates ultraconserved enhancer methylation and the differential transcriptional control of adjacent genes. *Development.* 2013; 140(21):4407–4416. [PubMed: 24089468]
153. Cajigas I, Leib DE, Cochrane J, Luo H, Swyter KR, Chen S, Clark BS, Thompson J, Yates JR 3rd, Kingston RE, Kohtz JD. Evf2 lncRNA/BRG1/DLX1 interactions reveal RNA-dependent inhibition of chromatin remodeling. *Development.* 2015; 142(15):2641–2652. [PubMed: 26138476]
154. Kraus P, Sivakamasundari V, Lim SL, Xing X, Lipovich L, Lufkin T. Making sense of Dlx1 antisense RNA. *Dev Biol.* 2013; 376(2):224–235. [PubMed: 23415800]
155. Cobos I, Calcagnotto ME, Vilaythong AJ, Thwin MT, Noebels JL, Baraban SC, Rubenstein JL. Mice lacking Dlx1 show subtype-specific loss of interneurons, reduced inhibition and epilepsy. *Nat Neurosci.* 2005; 8(8):1059–1068. [PubMed: 16007083]
156. Jones DL, Howard MA, Stanco A, Rubenstein JL, Baraban SC. Deletion of Dlx1 results in reduced glutamatergic input to hippocampal interneurons. *J Neurophysiol.* 2011; 105(5):1984–1991. [PubMed: 21325686]
157. Petryniak MA, Potter GB, Rowitch DH, Rubenstein JL. Dlx1 and Dlx2 control neuronal versus oligodendroglial cell fate acquisition in the developing forebrain. *Neuron.* 2007; 55(3):417–433. [PubMed: 17678855]
158. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene.* 1991; 108(2):193–199. [PubMed: 1660837]
159. Stuhmer T, Anderson SA, Ekker M, Rubenstein JL. Ectopic expression of the Dlx genes induces glutamic acid decarboxylase and Dlx expression. *Development.* 2002; 129(1):245–252. [PubMed: 11782417]
160. Sauvageau M, Goff LA, Lodato S, Bonev B, Groff AF, Gerhardinger C, Sanchez-Gomez DB, Hacısuleyman E, Li E, Spence M, Liapis SC, Mallard W, Morse M, Swerdel MR, D'Ecclesiss MF, Moore JC, Lai V, Gong G, Yancopoulos GD, Friendwey D, Kellis M, Hart RP, Valenzuela DM, Arlotta P, Rinn JL. Multiple knockout mouse models reveal lincRNAs are required for life and brain development. *elife.* 2013; 2:e01749. [PubMed: 24381249]
161. Grote P, Herrmann BG. The long non-coding RNA Fendrr links epigenetic control mechanisms to gene regulatory networks in mammalian embryogenesis. *RNA Biol.* 2013; 10(10):1579–1585. [PubMed: 24036695]
162. Grote P, Wittler L, Hendrix D, Koch F, Wahrisch S, Beisaw A, Macura K, Blass G, Kellis M, Werber M, Herrmann BG. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. *Dev Cell.* 2013; 24(2):206–214. [PubMed: 23369715]

163. McEvelly RJ, de Diaz MO, Schonemann MD, Hooshmand F, Rosenfeld MG. Transcriptional regulation of cortical neuron migration by POU domain factors. *Science (New York, NY)*. 2002; 295(5559):1528–1532.
164. Sugitani Y, Nakai S, Minowa O, Nishi M, Jishage K, Kawano H, Mori K, Ogawa M, Noda T. Brn-1 and Brn-2 share crucial roles in the production and positioning of mouse neocortical neurons. *Genes Dev*. 2002; 16(14):1760–1765. [PubMed: 12130536]
165. Dominguez MH, Ayoub AE, Rakic P. POU-III transcription factors (Brn1, Brn2, and Oct6) influence neurogenesis, molecular identity, and migratory destination of upper-layer cells of the cerebral cortex. *Cereb Cortex (New York, NY)*. 1991. 2013; 23(11):2632–2643.
166. Goff LA, Groff AF, Sauvageau M, Traves-Gibson Z, Sanchez-Gomez DB, Morse M, Martin RD, Elcavage LE, Liapis SC, Gonzalez-Celeiro M, Plana O, Li E, Gerhardinger C, Tomassy GS, Arlotta P, Rinn JL. Spatiotemporal expression and transcriptional perturbations by long noncoding RNAs in the mouse brain. *Proc Natl Acad Sci U S A*. 2015; 112(22):6855–6862. [PubMed: 26034286]
167. Eissmann M, Gutschner T, Hammerle M, Gunther S, Caudron-Herger M, Gross M, Schirmacher P, Rippe K, Braun T, Zornig M, Diederichs S. Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. *RNA Biol*. 2012; 9(8):1076–1087. [PubMed: 22858678]
168. Nakagawa S, Ip JY, Shioi G, Tripathi V, Zong X, Hirose T, Prasanth KV. Malat1 is not an essential component of nuclear speckles in mice. *RNA (New York, NY)*. 2012; 18(8):1487–1499.
169. Zhang B, Arun G, Mao YS, Lazar Z, Hung G, Bhattacharjee G, Xiao X, Booth CJ, Wu J, Zhang C, Spector DL. The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. *Cell Rep*. 2012; 2(1):111–123. [PubMed: 22840402]
170. Oliver PL, Chodroff RA, Gosal A, Edwards B, Cheung AF, Gomez-Rodriguez J, Elliot G, Garrett LJ, Lickiss T, Szele F, Green ED, Molnar Z, Ponting CP. Disruption of Visc-2, a brain-expressed conserved long noncoding RNA, does not elicit an overt anatomical or behavioral phenotype. *Cereb cortex (New York, NY)*. 1991. 2015; 25(10):3572–3585.
171. Sunwoo H, Dinger ME, Wilusz JE, Amaral PP, Mattick JS, Spector DL. MEN epsilon/beta nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles. *Genome Res*. 2009; 19(3):347–359. [PubMed: 19106332]
172. Sasaki YT, Ideue T, Sano M, Mituyama T, Hirose T. MENepsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles. *Proc Natl Acad Sci U S A*. 2009; 106(8):2525–2530. [PubMed: 19188602]
173. Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A, Lawrence JB. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. *Mol Cell*. 2009; 33(6):717–726. [PubMed: 19217333]
174. Fox AH, Bond CS, Lamond AI. P54nrb forms a heterodimer with PSP1 that localizes to paraspeckles in an RNA-dependent manner. *Mol Biol Cell*. 2005; 16(11):5304–5315. [PubMed: 16148043]
175. Chen LL, Carmichael GG. Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA. *Mol Cell*. 2009; 35(4):467–478. [PubMed: 19716791]
176. Nakagawa S, Naganuma T, Shioi G, Hirose T. Paraspeckles are subpopulation-specific nuclear bodies that are not essential in mice. *J Cell Biol*. 2011; 193(1):31–39. [PubMed: 21444682]
177. Nakagawa S, Shimada M, Yanaka K, Mito M, Arai T, Takahashi E, Fujita Y, Fujimori T, Standaert L, Marine JC, Hirose T. The lncRNA Neat1 is required for corpus luteum formation and the establishment of pregnancy in a subpopulation of mice. *Development*. 2014; 141(23):4618–4627. [PubMed: 25359727]
178. West JA, Mito M, Kurosaka S, Takumi T, Tanegashima C, Chujo T, Yanaka K, Kingston RE, Hirose T, Bond C, Fox A, Nakagawa S. Structural, super-resolution microscopy analysis of paraspeckle nuclear body organization. *J Cell Biol*. 2016; 214(7):817–830. [PubMed: 27646274]
179. Nishimoto Y, Nakagawa S, Hirose T, Okano HJ, Takao M, Shibata S, Suyama S, Kuwako K, Imai T, Murayama S, Suzuki N, Okano H. The long non-coding RNA nuclear-enriched abundant transcript 1_2 induces paraspeckle formation in the motor neuron during the early phase of

- amyotrophic lateral sclerosis. *Mol Brain*. 2013; 6:31.doi: 10.1186/1756-6606-6-31 [PubMed: 23835137]
180. Ip JY, Sone M, Nashiki C, Pan Q, Kitaichi K, Yanaka K, Abe T, Takao K, Miyakawa T, Blencowe BJ, Nakagawa S. Gomafu lncRNA knockout mice exhibit mild hyperactivity with enhanced responsiveness to the psychostimulant methamphetamine. *Sci Rep*. 2016; 6:27204. [PubMed: 27251103]
181. Tsuiji H, Yoshimoto R, Hasegawa Y, Furuno M, Yoshida M, Nakagawa S. Competition between a noncoding exon and introns: Gomafu contains tandem UACUAAC repeats and associates with splicing factor-1. *Genes Cells*. 2011; 16(5):479–490. [PubMed: 21463453]
182. Ishizuka A, Hasegawa Y, Ishida K, Yanaka K, Nakagawa S. Formation of nuclear bodies by the lncRNA Gomafu-associating proteins Celf3 and SF1. *Genes Cells*. 2014; 19(9):704–721. [PubMed: 25145264]




Fig. 9.1.

Graph depicting the number of lncRNAs identified in given species relative to the encephalization quotient (EQ). EQ is indicative of the deviation from the expected brain size based on body mass, with larger numbers indicative of larger than expected brain size (normalized to the cat brain/body ratio equivalent) [17, 18]. Number of lncRNAs for a given species is taken from Gencode (*Homo sapiens*, Version 25 (March 2016, GRCh38)—Ensembl 85) [19, 20] or from published reports [21]. Trendline represents nonlinear fit with $R^2 = 0.8343$









Effects of genetic models for lncRNA loss of function	Potential Outcomes
	lncRNA loss of function only (ideal); effect on chromatin structure?
	Loss of lncRNA expression (ideal); effect on chromatin structure?
	Loss of lncRNA and enhancer sequence; neighboring gene expression is affected
	Loss of lncRNA expression; effect on chromatin looping?
	Loss of lncRNA and promoter sequence of neighboring protein coding gene; altered protein coding gene expression
	Transcription of lncRNA inhibited alteration to protein coding gene promoter sequence; altered protein coding gene expression?
	Loss of lncRNA and protein coding gene sequence
	Transcription of lncRNA inhibited alteration to protein coding gene promoter and primary sequence

Fig. 9.2. Examples of the effects of lncRNA deletion or insertion of a strong transcriptional stop (pA) on genomic architecture and neighboring gene expression. Careful design of genetic strategies targeting lncRNA loss of function must be employed to ensure that resulting outcomes are the result of lncRNA function and not a consequence of changes to the genome architecture that result in unintended outcomes